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nanotube surface morphologies. “Planning” included the following activities: selection of 
number/type of samples (for each experiment) and characterization techniques, sample 
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Beaumont and MTU. Erin was actively involved with data collection for all 
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Following experimentation and data collection, Erin analyzed all results, and 
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Abstract 
 
 
Introduction:  As joint arthroplasty surgical procedures increase annually, the 
development of new strategies, including novel materials and surface modifications, to 
attain solid bone-implant fixation are needed to increase implant terms of service. In this 
study, we evaluate two morphologies of titania nanotubes in both in vitro and in vivo 
experiments to quantify osseointegrative potential and material-level biocompatibility. 
 
Materials and Methods:  Samples were prepared via an electrochemical etching 
process. Two different titania nanotube (TiNT) morphologies were produced, Aligned 
and Trabecular. For the in vitro experiment, Sprague Dawley (SD) rat marrow-derived 
bone marrow cells (BMC) were seeded on samples. Alkaline phosphatase (ALP) activity, 
osteocalcin (OC) expression, expression of relevant genes as well as cell attachment and 
morphology were assessed. In the first in vivo experiment, Kirschner wires were 
implanted unilaterally into SD rat femora with a TiNT-etched or unmodified (Control) 
implant. General health assessments and weekly body weights were recorded. At a 12-
week endpoint, hematologic, systemic metal ion, and histologic analyses were performed. 
For the second in vivo experiment, Kirschner wires were implanted bilaterally into SD rat 
femora, with a TiNT-etched implant in one femora and unmodified (Control) implant as 
an internal control. At 4- and 12-week endpoints, femora were assessed via 
biomechanics, undecalcified histology, micro-computed tomography (μCT), and 
backscattered electron imaging (BEI) to characterize de novo bone formation.    
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Results:  In vitro experiments demonstrated BMC attachment and differentiation into 
osteoblasts as well as greater ALP activity, OC expression, total cell counts, and gene 
expression (of Col1a1, IGF-1, and osteonectin) on TiNT surfaces versus Controls. Cells 
on TiNT-etched substrates were smaller in diameter and more eccentric than Controls. In 
the first in vivo experiment, there were significant differences in body weight between 
groups at Weeks 9 and 11. There were no significant differences in red or white blood 
cell function between TiNT groups and Control. Aluminum levels in the lungs were 
significantly greater in the Trabecular TiNT group compared to Control. Histologic 
analysis showed significantly fewer granulocytes and neutrophils in the distal region of 
Trabecular TiNT-implanted femora as well as significantly fewer foreign body 
giant/multinucleated cells and neutrophils in the midshaft region of Aligned TiNT-
implanted femora versus Controls. In the second in vivo experiment, at 12 weeks, µCT 
analysis showed TiNT implants generated greater bone formation than Controls. 
Histologic analysis demonstrated 1.5 times greater bone-implant contact in TiNT groups 
than Controls at 12 weeks. TiNT groups exhibited 1.3 to 3.7 times greater strength of 
fixation than Controls during pull-out testing. 
 
Discussion and Conclusions:  In vitro data confirmed BMC attachment and 
differentiation into osteoblasts as well as osteoblastic phenotypic behavior. A clinically-
relevant in vivo model of femoral intramedullary fixation, showed increased bone 
formation and quality in femora implanted with TiNT-etched implants versus Controls. A 
second in vivo study showed that TiNT surfaces do not generate systemic effects and may 
beneficially modulate the periprosthetic inflammatory environment. 
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Chapter 1: 
Introduction 
 
 
This work builds on the body of work of former and current researchers within the 
Multi-Scale Technologies Institute (MuSTI) group investigating titania nanotube (TiNT) 
arrays for biomedical applications. In this paper, orthopaedic applications of the material 
will be examined and discussed.  
 The total number of joint arthroplasty surgical procedures continues to increase 
year over year due to a confluence of factors, including population aging, obesity, 
increasing rates of arthritis, and bone metabolic disorders.[1-3] For implants requiring 
bony fixation, efficient, early-term osseointegration as well as a stable bone-implant 
interface are early indicators of clinical success. Long-term, implant performance, 
especially related to wear behavior, is one key factor in determining need for a revision 
procedure. Poor osseointegration may lead to implant subsidence and/or malalignment, 
which results in altered joint kinematics and accelerated wear and damage to 
components. Additionally, surface treatments and coatings applied to orthopaedic 
implants may dislodge during implantation or cyclic loading, leading to third-body wear 
and eventually the need for early revision surgery.  
 TiNT surfaces may provide both early- and long-term improvements in 
osseointegration as a result of increased osteoblast attachment and bone mineralization. 
Long-term implant performance may also be achieved via a reduction in TiNT particle  
shedding and a diminished inflammatory response to TiNT surfaces and debris compared 
 
Material contained in this chapter is planned for journal submission. 
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to other orthopaedic implant materials. 
 The goal of the proposed experimentation discussed in this document, was to 
assess the osteoconductive and biocompatibility properties of Aligned and Trabecular 
TiNT surfaces via both in vitro and in vivo experimentation. Chapters 2 and 3 provide 
additional background about the principles of bone formation, orthopaedic implants, and 
TiNT surfaces. Specifically, Chapter 2 provides an overview of the process of bone tissue 
formation and cycle of regeneration, current orthopaedic implant technologies, and 
material- level requirements of metal alloys. Chapter 3 introduces TiNT surfaces, 
including advantages of the surface modification techniques and material processing. 
In Chapter 4, preliminary in vitro experimentation performed to characterize the 
cellular response and behavior on TiNT surfaces, providing information regarding 
baseline biocompatibility with respect to cell survivability are described. Osteoblastic 
differentiation of marrow-derived stem cells cultured on TiNT surfaces was assessed by 
assaying osteogenic markers at both the protein- and mRNA-level, in order to generate 
information about TiNT performance in an environment simulating a marrow cavity.   
Chapters 5 and 6 detail the translation of our in vitro results into in vivo models. 
In vivo biocompatibility was evaluated by assessing longitudinal animal weights, remote 
organ weights, metal ion levels in remote organs and whole blood, hematology, and 
undecalcified histology (Chapter 5). The ability of Aligned and Trabecular TiNT-
modified implant surfaces to facilitate in vivo bone ingrowth and ongrowth was 
investigated in a rat femoral intramedullary implant model, using a combination of 
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biomechanics, undecalcified histology, microcomputed tomography (μCT) and 
backscattered electron imaging (BEI) characterization techniques (Chapter 6).  
Three concepts of future directions for continued evaluation and modification of 
titania nanotube surfaces are presented in Chapter 7. The first concept focuses on local 
delivery of stromal cell-derived factor 1 (SDF-1β), which increases recruitment of stem 
cells that will subsequently stimulate bone formation, from titania nanotube surfaces. 
Second, a murine air pouch model of wear debris-induced osteolysis is proposed, to 
compare titania nanotube and conventional wear debris. Finally, a model of total hip 
arthroplasty in a goat is described, which will fulfill the prerequisite of in vivo testing in a 
higher phylogenic species, as required by the United States Food and Drug 
Administration. 
Chapter 8 contains the conclusions of the experimentation and results presented in 
this document, based on our initial hypotheses that TiNT surfaces provide both early- and 
long-term improvements in osseointegration-related outcomes as a result of increased 
osteoblast attachment and bone mineralization as well as equivalent biocompatibility and 
toxicity, compared to unmodified titanium alloy surfaces.  
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Chapter 2: 
Specific Considerations of Orthopaedic Implants for Osseointegration 
Applications 
 
 
2.1 Introduction 
In 2010, 719,000 primary total knee arthroplasty and 332,000 total hip 
arthroplasty (THA) surgeries were performed, according to the National Hospital 
Discharge Survey prepared by the Centers for Disease Control and Prevention.[4] Solid 
biologic fixation at the bone-implant interface provides long-term stability of arthroplasty 
and other orthopaedic implant components that require osseointegration. Poor 
osseointegration may lead to implant subsidence and/or malalignment, resulting in altered 
joint kinematics and accelerated wear and damage to components. 
 
2.2 Bone Formation for Ingrowth and Ongrowth of Orthopaedic Implants 
 Bone is a multifaceted organ composed of osseous, nervous, fibrous, muscle, and 
epithelial tissues.[5] The 206-bone adult human skeletal system has various roles, 
including structural support of soft tissues and musculature, protection of delicate organs 
(e.g. brain, heart, uterus), sites of attachment for muscles and subsequent crosstalk, 
regulation of calcium and phosphorus levels as a dynamic reservoir as well as collection 
and quarantine of toxic materials (e.g. lead).[6-9]    
 Compared to other tissues in the body, bone tissue is less cellular. Bone is formed 
by a combination of several types of extracellular matrices, including mineralized bone 
extracellular matrix (ECM) as well as unmineralized osteoid and lacunar ECM. Primarily 
composed of mineralized bone ECM produced by osteoblast cells and considered a 
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composite material, bone tissue has many constituents, including minerals (e.g. 
magnesium, sodium), protein, water, salts (e.g. insoluble calcium and phosphorus as 
hydroxyapatite), lipids, glycoproteins, and proteoglycans. Osteoid and lacunar 
extracellular matrices also have important roles in bone tissue production and 
maintenance. Osteoid is unmineralized tissue that forms a temporary matrix, defining the 
regions that will eventually mineralize to form mature bone. The role of the 
unmineralized lacunar ECM, which surrounds osteocyte cells, is also related to regulating 
osteocyte function.[10] 
 There are two distinct structures of bone tissue, trabecular and cortical, which are 
formed through primary (woven) and secondary (lamellar) tissue organization. 
Trabecular bone has a sponge-like appearance with macroscale porosity. The most 
distinguishing characteristic of trabecular bone structure is the system of flat, thin plates 
and cylindrical rods that serve as mechanical struts. These struts are an indicator of bone 
disease, quality and overall health. In metabolic disease processes, such as osteoporosis, 
as strut thickness decreases, subsequently strut interconnectivity decreases and porosity 
increases, resulting in decreased mechanical strength and support. Bone marrow fills the 
negative space surrounding the struts. Located at the proximal and distal regions of long 
bones, trabecular bone effectively absorbs impact forces near joints. In contrast, cortical 
bone is extremely dense and compacted. Cortical bone surrounds the long bones. In the 
diaphyseal (midshaft), the cylindrical region of a long bone, cortical bone supports 
weight-/load-bearing and surrounds the intramedullary canal. Moving proximally or 
distally, the thickness of the cortical bone decreases in the metaphyses and epiphyses, 
forming a thin shell. Because these regions contain a significant amount of trabecular 
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bone, the cortical and trabecular bone effectively load-share, with the evenly-dispersed 
trabecular bone enduring most of the mechanical force.[10] 
 In total hip arthroplasty, the process of bone formation and subsequent 
osseointegration begin at the time of implantation with a process of injury and repair. 
During repair, intramembranous bone formation occurs at the bone-implant interface, 
which leads to osseointegration depending on implant material, implant surface 
morphology (e.g. pore size, surface chemistry), implant stability, and bony 
apposition.[10] In intramedullary canals, implants are in contact with bone marrow, 
containing stem and progenitor cell populations. The stem cell populations include 
hematopoietic stem cells (HSC) and nonhematopoietic mesenchymal stem cells (MSC). 
HSC may shift into various immune cell types, including erythrocytes (red blood cells), 
granulocytes (i.e. basophils, neutrophils, eosinophils, monocytes), and lymphocytes (i.e. 
dendritic cells, plasma cells, T cells, B cells, T natural killer cells).[11] Conversely, MSC 
may differentiate toward multiple mesodermal tissue lineages, including bone (i.e. 
osteoblast), muscle (i.e. myocyte), cartilage (i.e. chondrocyte), tendon or ligament (i.e. 
fibroblast), and adipose (i.e. adipocyte).[12-16] If conditions (e.g. implant-specific, gene-
/protein-based regulators and markers) are appropriate and supportive, MSC will be 
induced to commit to an osteoblastic lineage, proliferate, build a mature bone matrix, and 
finally mineralize. The final stage of osteoblastic differentiation is transition into an 
osteocyte, which resides within the lacunae of mineralized tissue (Figure 2.1). 
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Figure 2.1. Illustration of the cycle of osteoblatic differentiation at the cellular level. 
Figure adapted from Miller et al.[10] 
  
 Protein- and molecular-level regulators guide each step in the cycle of 
osteoblastic differentiation. Numerous molecular signals, including transforming growth 
factor beta (TGF-β) superfamily proteins, push uncommitted stem cells toward a 
mesenchymal lineage.[10] Then, MSC are driven toward an osteoblastic phenotype by 
specific molecular cues, including growth factors such as platelet-derived growth factor 
(PDGF), insulin growth factor 1 (IGF-1), and bone morphogenetic protein 2 (BMP-2). At 
this stage, the protein runt-related transcription factor 2 (RUNX2) advances proliferation 
to the preosteoblast stage; however, if peroxisome proliferator-activated receptor gamma 
2 (PPARγ2) is expressed instead, the stromal cells will progress to adipocyte (fat cell) 
lineage.[17, 18] To further promote osteoblast cell differentiation toward mature 
osteoblasts, glucocorticoid, Vitamin D, insulin growth factor 2 (IGF-2), and 
prostaglandin E2 (PGE-2) are required.[10]  
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 In addition to osteoblastic differentiation and subsequent mineralization, there is a 
coupled process of bone remodeling between bone anabolism and bone catabolism. In 
normal bone remodeling, during the early stages of bone tissue mineralization, anabolism 
exceeds catabolism. As new bone tissue matures, osteoclasts, derived from HSC and 
composed of fused monocytes, resorb bone in order to contribute to the overall bone 
structure. Via the receptor activator of necrosis factor - κ B ligand/ receptor activator of 
necrosis factor - κ B/osteoprotegerin (RANKL/RANK/OPG) pathway, osteoclasts and 
osteoclast precursors express the RANK receptor on the surface of the cells, while 
osteoblasts express RANKL. RANKL then attaches to RANK, which promotes 
proliferation and differentiation of cells to form osteoclasts as well as prevent cell 
apoptosis. OPG, which is also produced by osteoblasts, modulates RANKL by impeding 
the attachment between RANKL and RANK.[19, 20] Systemically, many other hormones 
and genes also participate in the dynamic process of bone formation and remodeling. 
Estrogen hormones inhibit osteoclasts precursors, decrease the pro-inflammatory 
cytokine interleukin 6 (IL-6), and increase rates of osteoblast survival. [18, 21, 22] 
Parathyroid hormone (PTH) also stimulates osteoblast activity and acts in concert with 
RUNX2 to advance osteoprogenitor cells to preosteoblasts by increasing expression of 
RANKL.[18, 23] Insulin growth factor 1 (IGF-1) increases osteoblast function and 
cortisol causes osteoblast apoptosis.[18, 22, 24] Calcitonin inhibits osteoclastic activity, 
while thyroid hormone and Vitamin A stimulate osteoclasts.[18, 24] Locally, numerous 
endothelial, neurologic, and marrow-derived growth factors, such as fibroblast growth 
factor (FGF), TGF-β, and integration site-1 + wingless in Drosophila (Wnt), 
respectively.[17, 18] Damage to bone tissue, mechanical loading (e.g. exercise, body 
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weight, weightbearing status) as well as local release of cytokines and growth factors in 
response to systemic hormones (e.g. estrogen) all influence the bone remodeling process. 
Other factors may affect the process, but remain unknown.[25] 
  
2.3 Material Selection of Orthopaedic Implants for Osseointegration 
 A limited number of metals are approved by the American Society for Testing 
and Materials (ASTM) and Food and Drug Administration (FDA) for implantation, 
including titanium, stainless steel, cobalt-chromium-molybdenum (Co-Cr-Mo), and some 
refractory (e.g. zirconium, tantalum) alloys. Titanium-6Aluminum-4Vanadium (Ti-6Al-
4V) alloy is commonly used for THA femoral stem and TKA tibial tray components, due 
to its chemical inertness (biocompatibility) and corrosion resistance as well as torsional 
and axial stiffness moduli similar to bone. This match between mechanical properties of 
Ti-6Al-4V and bone results in a reduction of stress shielding, compared to other alloys. 
Titanium alloys also maintain a passive oxide layer (TiO2), which promotes corrosion 
resistance. However, Ti-6Al-4V has lower hardness values, approximately 15% less than 
Co-Cr-Mo alloys, and decreased wear resistance, making Co-Cr-Mo alloys a superior 
material for articulation-based conditions.[26] Several seminal studies reported 
successful osseointegration of titanium implants, which has propelled continued research 
of the process.[27-29] 
 These approved metal alloys are also used to modify orthopaedic implant 
surfaces. Surface modification techniques, especially macroscale and microscale 
coatings, have historically been used to promote early and long-term osseointegration of 
non-articular joint replacement component surfaces. Current surface modification 
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techniques incorporate desired composition and surface chemistry, but lack nanoscale 
topographical features beneficial for cell attachment (Table 2.1).  
 
Table 2.1.  Current surface modification techniques of orthopaedic implants. 
Coating/Modification Material 
Roughened Titanium Alloys 
Bead Titanium and Cobalt-Chromium-Molybdenum Alloys 
Wire/Fiber Mesh Titanium Alloys 
Plasma-Spray Titanium Alloys 
Bioactive Non-
Metallics 
Hydroxyapatite 
Growth Factors Transforming growth factor beta (TGF-β), Bone morphogenetic protein 2 
(BMP-2) 
  
 These coatings, however, are subjected to shear loads during surgical 
implantation, contact with surgical tools, and eventually micromotion at the bone-implant 
interface during a patient’s activities of daily living. As a result, these coatings may 
separate from the substrate, generating third-body wear debris that increases mechanical 
wear of bearing surfaces (Figure 2.2). Additionally, local phagocytic cells encountering 
this debris may initiate a biologic cascade leading to periprosthetic osteolysis. The body’s 
immune response to wear debris, which is dependent on particulate composition, 
concentration, and morphology, results in osteoclastic bone resorption around the 
implant, component loosening, and ultimately revision surgery.[30]  
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Figure 2.2. Digital and scanning electron images of a retrieved total ankle arthroplasty 
prosthesis. Pictured are a (A) digital image of macroscale architecture on region of 
surface-modified titanium alloy for osseointegration of TAA titanium tibial component, 
(B) digital image of embedding damage of retrieved TAA polyethylene liner, (C) 
representative scanning electron micrograph demonstrating effect of embedding damage 
to polyethylene component (scale bar: 100 µm), (D) representative scanning electron 
micrograph showing severe polyethylene damage and sloughing of wear debris (scale 
bar: 50 µm). 
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Chapter 3: 
Titania Nanotube Surfaces for Orthopaedic Implant Applications 
 
3.1 Introduction 
 When cells encounter implant surfaces, the structure/topography, roughness, 
mechanical properties (specifically, stiffness), phase structure, and surface chemistry all 
affect the rate and quality of cell attachment as well as the propensity for cells to 
differentiate to an osteoblastic phenotype.[31-36] These material properties are one factor 
determining whether fibrous or bone tissue are formed.[31] Nanoscale metals, with grains 
less than 100 nm in diameter, have been increasing evaluated for biomedical, and 
specifically orthopaedic, applications with the hypotheses that matching materials with 
nanoscale roughness relative to nanoscale bone tissue structures will increase 
osseointegration, decrease stress shielding, and decrease wear debris generation. [37-40] 
In comparison, “conventional” materials, currently in-use, are characteristically “micro-
rough” (i.e. rough at the micron scale) and “nano-smooth” (i.e. smooth at the nanoscale).  
Webster, et al. assessed osteoblast cell adhesion on nanophase and conventional 
titanium, Ti-6Al-4V, and Co-28Cr-6Mo surfaces. Osteoblast adhesion was observed on 
both the nanophase and conventional surfaces, preferentially at the particle boundaries; 
however, the nanophase surfaces demonstrated increased osteoblast adhesion, possibly 
due to the greater number of boundaries on the nanophase surfaces.[37] In a separate 
study Gutwein, et al. investigated osteoblast response between nanoscale and 
conventional (i.e. micron scale) titania particles at various concentrations and confirmed  
 
Material contained in this chapter is planned for journal submission. 
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increased osteoblast apoptosis in the presence of conventional versus nanophase 
particulates.[41] Nanotextured metallic materials, with nanotopographical features, have 
also been developed using various techniques (e.g. oxidation-controlled, alkali-heat 
treatment, hydrothermal, laser ablation) and investigated, with respect to cell adhesion, 
differentiation, and proliferation.[42-48] 
 A novel surface treatment, titania nanotubes etched via an electrochemical 
anodization process from titanium alloy, represents a new, industrially-viable method to 
enhance osseointegration of orthopaedic implants. [49] The processing conditions and 
resultant material structure of titania nanotube surfaces prepared via anodic oxidation 
were first described in 2001.[50] The group used a 0.5-3.5 wt% hydrofluoric acid 
solution to etch aligned nanotubes. When voltage increased, the nanotube diameter also 
increased, producing tubes with diameters between 25 and 65 nm.[50]  
 Subsequent research has focused on modification of processing and post-
processing conditions, such as reformulating the electrolyte solution, adjusting voltage as 
well as varying the etching time and temperature, to achieve distinct surface properties 
and features.[51-53] Recent work has also included the use of different titania alloys and 
integration other materials into the etching process, coating applications to the titania 
arrays for enhancing antibacterial or osseointegration as well as pharmacologic agents 
and small molecules to load nanotubes for augmenting and modifying biologic 
processes.[54-63]  
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3.1.1 Previous In Vitro Studies of Titania Nanotube Surfaces for Osseointegration 
Applications                
                                                                                                                                                                                                  
Previous studies have demonstrated the biocompatible and osteoconductive 
properties of aligned, vertically-oriented titania nanotube arrays etched from Ti-6Al-4V 
alloy and unmodified by post-processing methods.  
 Nanotube diameter has been studied in the context of cellular response, using 
various cell lines. One study cultured human mesenchymal stem cells (hMSC; human 
umbilical cord-derived) onto titania nanotube surfaces with a range of diameters (15, 20, 
30, 50, 70, and 100 nm), and showed that 15 nm-diameter surfaces generated greater 
mineralization (alizarin red staining) and osteocalcin expression than other groups, 
including unmodified control surfaces.[64] Park, et al. concluded that nanotubes less than 
30 nm and greater than 50 nm impeded mesenchymal stem cell adhesion and spreading; 
[65] however, a separate study showed hMSC attachment on 30 nm diameter tubes, 
although subsequent differentiation did not transpire. When tube diameter was increased 
to 70-100 nm, there was a 10-fold increase in stem cell elongation as well as comparative 
increases in alkaline phosphatase (ALP), osteocalcin, and osteopontin activity.[66] For 
reference, hMSC (placental-derived, P6), on average, are approximately 26.5 μm in 
diameter (range, 15 to 50).[67] With rat-derived MSCs cultured onto 80 nm-diameter 
nanotubes, Popat, et al. also showed greater ALP activity as well as calcium and 
phosphorus deposition on titania nanotube surfaces compared to unmodified 
titanium.[68] After seeding human osteoprogenitor cells onto TiNT surfaces with 120 nm 
tube diameters, Das, et al. stained for alkaline phosphatase and showed increased cell 
counts with osteoblastic phenotype, and again documented filopodia attachment to 
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nanotubes.[69] Yu, et al. seeded mouse preosteoblast cells (MC3T3-E1) onto titania 
nanotube surfaces, and reported greater cell adhesion, ALP activity, and mineralization 
on titania nanotube arrays with diameters ranging from 20-70 nm versus 100-120 nm.[70] 
Large diameter, 150-470 nm, titania nanotube surfaces were seeded with mouse 
preosteoblast cells. The greatest cell elongation and cell attachment were observed on 
surfaces with 150 nm diameter and 470 nm diameter nanotubes, respectively. Maximum 
ALP activity was measured on 150 nm diameter surfaces, and ALP activity decreasing as 
diameter increased.[71] 
 The phases of titanium, amorphous, anatase or rutile (i.e. annealed or 
unannealed), have been the focus of several studies. In double-concentration simulated 
body fluid alone for 7 days, Fan, et al. showed that titania nanotube surfaces induced 
apatite formation, with greater calcium and phosphorus deposition on annealed versus 
unannealed titania nanotube surfaces.[72] Shin, et al. demonstrated the hydrophilicity of 
titania nanotube surfaces, due to the anodization process, compared to unmodified 
titanium. Surface hydrophilicity was increased additionally by subjecting samples to a 
post-anodization annealing process,[73] and a follow-up study showed that hydrophilic 
surfaces allowed greater mouse preosteoblast cell spreading.[74] Hamlekhan, et al. 
investigated aging of titania nanotube surfaces (i.e. conversion from anatase to rutile as 
indicated by loss of hydrophilicity), and confirmed crystallinity and morphology control 
hydrophilicity, with nanotube surfaces anodized at 60V and annealed at 600°C 
maintaining hydrophilic properties for 60 days. The authors further concluded an 
annealing temperature of at least 450°C maintains hydrophilicity for approximately 2 
weeks.[75] 
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 Numerous studies used cell lines with preosteoblastic or osteoblastic lineages to 
evaluate titania nanotube surfaces. In two studies, Oh, et al. measured mouse 
preosteoblast cell adhesion and spreading on TiNT surfaces, and observed increased cell 
counts, hydroxyapatite deposition, and cell filopodia attachment within nanotube 
pores.[76, 77] Shokuhfar, et al. assessed mouse preosteoblast cell attachment and density 
by seeding onto TiNT surfaces with nanotubes averaging 100 nm in diameter, and 
confirmed similar trends. Focused ion beam milling provided visualization of individual 
cell attachment via filopodia to nanotubes.[74] When comparing titania nanotubes 
ranging from 30 nm to 100 nm diameter cultured with mouse preosteoblast cells, ALP 
activity on titania nanotube surfaces (all diameters) significantly increased compared to 
controls, and increased proportionally with nanotube diameter.[78] Culturing fetal rat 
calvarial cells on TiNT surfaces demonstrated equivalent cell viability of TiNT and 
unmodified titania surfaces, yet TiNT surfaces exhibited increased ALP activity as well 
as bone sialoprotein, osteocalcin, and PGE-2 expression.[79, 80] A separate study that 
seeded titania nanotube surfaces with primary rat calvarial osteoblast cells also showed 
increased ALP activity, compared to smooth and acid-etched titania surfaces.[81]  
 Several studies investigated gene-level response to titania nanotube surfaces. 
Filova, et al. discussed the importance of the wall thickness of the nanotubes, and seeding 
human sarcoma osteogenic 2 cells (Saos-2) onto titania nanotube arrays with wall 
thicknesses from 14 to 19 nm, on average. After 7 days, greater activity of ALP, Type I 
collagen, and osteopontin were measured on samples with thinner walls.[82] Pozio, et al. 
conducted a gene-based analysis of TiNT surfaces seeded for 15 and 30 days with human 
osteoblasts and found selected genes related to osteoblast differentiation were 
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upregulated, including RUNX2.[83] Bacterial adhesion on titania nanotube surfaces as a 
function of nanotube diameter was investigated by Ercan, et al. Both Staphylococcus 
epidermis and Staphylococcus aureus were cultured on annealed and unannealed titania 
nanotube surfaces with 20, 40, 60, and 80 nm-diameter nanotubes as well as unmodified, 
conventional titanium for 1 hour. Compared to control, annealing the surfaces decreased 
the number of dead bacteria adhering to surfaces, which can increase attachment and 
proliferation of live bacteria, and nanotube surfaces with larger individual nanotube 
diameters decreased the number of live bacteria. Annealing and surfaces with larger 
diameter nanotubes, in combination, exhibited the least adhesion of any groups.[84] 
 
3.1.2 Previous In Vivo Studies of Titania Nanotube Surfaces for Osseointegration 
Applications 
  
 In vivo studies provide an opportunity for translation of in vitro methods and 
results. Numerous studies have used animal-based models to evaluate osseointegration of 
aligned TiNT surfaces. This section will focus on TiNT surfaces etched from Ti-6Al-4V 
alloy, which are otherwise unmodified. 
 Implantation in a rodent model, to assess of biocompatibility of titania nanotube 
surfaces, was performed with two Lewis strain rats with a 4-week endpoint. Samples 
were implanted within a pocket between skin and muscle layers. Hematoxylin and eosin 
(H&E) showed a lack of fibrous tissue.[68] In a rabbit model, grit-blasted and TiNT-
etched (~90-108 nm diameter nanotubes; 3.75 mm diameter implant) screw implants 
were placed in femoral condyles for 6 weeks. Woven bone was observed in the periosteal 
region, while toluidine blue staining confirmed new bone formation in the endosteal 
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region. Quantifying bone formation around implants with backscattered electron imaging 
showed significantly greater bone formation around TiNT implants. Removal torque, a 
measurement of the bone-implant interfacial shear strength, was also significantly greater 
for the TiNT implants.[85] Bjursten, et al. implanted titania disks with titania nanotube 
and grit-blasted morphologies transversely onto rabbit tibiae. After a 4-week endpoint, 
samples were subjected to tensile testing, with titania nanotube-etched implants 
exhibiting significantly greater pull-out forces than grit-blasted implants. H&E staining 
demonstrated greater bone-implant contact, bone formation, and presence of calcium in 
tissue surrounding titania nanotube implants.[86] 
 Large animal species were used in several studies. Fan, et al. inserted cylindrical 
implants with three surfaces, annealed titania nanotubes, unannealed titania nanotubes, 
and porous titanium (control), transversely into canine femora for 3 months. Both the 
annealed and unannealed titania nanotube surfaces showed significantly greater 
biomechanical push-out strength. H&E staining showed de novo bone tissue formation on 
both titania nanotube surfaces.[72] In a minipig model, four implant types (unmodified as 
well as 30, 70, and 100 nm-diameter nanotube surfaces) were inserted into the front bone 
(skull) for endpoints at 3, 5, and 8 weeks. Gene expression analysis showed osterix 
(OSX), ALP, Type I collagen were significantly greater for 30, 70, and 100 nm-diameter 
nanotube surfaces, compared to control. Harvested implants were embedded and stained 
with methylene blue-basic fuchsin, which indicated significantly greater bone-implant 
contact for all titania nanotube surfaces at all timepoints, with the 70 nm-diameter 
nanotube surfaces demonstrating the most bone-implant contact.[87] Using a porcine 
(adult domestic) model, von Wilmowsky, et al. implanted TiNT-etched rods (30 nm 
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diameter nanotubes; 4.2 mm diameter implants) into the skull. Immunohistochemical 
analysis showed significantly increased Type I Collagen of TiNT implants versus 
Controls at Days 7, 14, and 30 postoperative, indicating positive effects of TiNT surfaces 
on bone formation. Imaging via scanning electron microscopy confirmed that nanotubes 
were intact, confirming that nanotube surfaces survived shear forces during 
implantation.[88] von Wilmowsky, et al. used the same model to investigate the effect of 
nanotube diameter on osseointegration. Titania nanotube surfaces with 15, 30, 50, 70, and 
100 nm diameters as well as unmodified controls were implanted. After harvesting 
implants in situ, implants were embedded, sectioned, and stained with toluidine blue, 
which showed significantly greater bone-implant contact for 50, 70, and 100 nm-diameter 
nanotube surfaces, compared to control. Additional immunohistochemical analysis 
showed greater stained areas of bone morphogenetic protein 2 (BMP-2) on 50, 70, and 
100 nm-diameter surfaces as well as osteocalcin on 70 nm-diameter surfaces, compared 
to control.[89]  
 
3.2 Titania Nanotube Surface Morphologies 
In the present study, two morphologies of titania nanotube surfaces, termed 
Aligned Titania Nanotubes (Aligned TiNT) and Trabecular Titania Nanotubes 
(Trabecular TiNT) were evaluated in vitro and in vivo (Figure 3.1). Aligned TiNT 
surfaces are characterized by vertically-oriented, hollow, tubular structures in parallel, 
resulting from post-anodization sonication. The Aligned TiNT arrays in this work 
contained nanotubes that were approximately 50 nm inside diameter and 1 μm in length. 
Trabecular TiNT surfaces exhibit a disordered morphology similar to trabecular bone. 
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The pore sizes in this morphology are highly variable, however larger pores are 
approximately 1 μm in diameter (Figure 3.1C). Also, some nanotubes were observed 
buried within the porous structure. While these nanotubes could not be measured with 
acceptable resolution, we anticipate these are similarly-sized to the nanotubes on the 
Aligned TiNT surfaces due to identical etching methods, as described in Section 3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Scanning electron micrographs of titania nanotube surfaces. (A) Aligned 
TiNT and (B,C) Trabecular TiNT surfaces. (A) Scale Bar: 500nm, (B) Scale Bar:  2 µm, 
(C) Scale Bar:  1 µm 
 
3.3 Material Processing of Titania Nanotube Surfaces  
 The samples for in vitro and in vivo studies were fabricated with titanium alloy 
(Ti-6Al-4V) sheet and Kirschner wires (Ti-6Al-4V ELI K-wire), respectively. As-
received sheet and wire material were polished with 600 grit abrasive sheet and deionized 
(DI) water, followed by a DI water rinse and air-drying. Acetone was applied to the 
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surfaces just prior to etching, and then air-dried. Etching was prevented on the trocar tip 
of the K-wires with a temporary coating of cyanoacrylate that was removed with acetone 
after anodization.  
 In a glass beaker, the samples (sheet or K-wires) were suspended on one side and 
connected to a variable DC power supply, as the anode. Diametrically opposed to the 
titanium sample, a small diameter graphite rod was also suspended in the beaker and 
connected to ground, as the cathode. The electrolyte solution contained 98 vol% ethylene 
glycol, 2 vol% deionized water, and 0.6 wt% NH4F. The NH4F was first dissolved in the 
DI water and then this solution was added to the ethylene glycol. The electrolyte was 
added to the beaker at a level just below the electrical connections. Before combining the 
NH4F and ethylene glycol, the NH4F was dissolved in DI water. With all materials and 
solutions in place, the power supply was engaged (+60 VDC) and etching continued for 
40 minutes.  
 After the etching period, the power supply was disengaged, samples were 
removed from the solution and subjected to a 1-minute rinse under water, and then air-
dried. Aligned TiNT surfaces resulted from ultrasonication in DI water for 2 minutes, 
however Trabecular TiNT surfaces received no additional ultrasonication. Sheet samples 
were sectioned into 10 mm x 10 mm coupons. The coating on the trocar tip of each K-
wire was removed, however no sectioning was required. Using a programmable 
annealing oven, with temperature increasing at 7.5°C per minute to a steady-state of 
450°C for a total heating time of 3 hours, samples were heat-treated to convert the 
amorphous titanium to crystalline anatase, which enhanced the hydrophilicity of the 
TiNT surfaces. After completely cooling the oven over approximately 5 hours, samples 
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were removed.[73] Control samples were prepared only by rinsing in DI water and air-
drying (Figure 3.2). 
 
 
 
 
 
 
Figure 3.2. Digital photograph showing the final appearance of coupon samples. (Left) 
TiNT-etched surfaces appear gold and smooth, compared to (right) unmodified control 
surfaces. 
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Chapter 4: 
In Vitro Assessment of Bone Marrow-derived Cells on Titania Nanotube 
Surfaces 
 
 
4.1 Introduction 
 
 Titania nanotube surfaces, both Aligned TiNT and/or Trabecular TiNT, may 
provide enhanced conditions for cell attachment compared to unetched titanium (Control) 
surfaces.[47] If initial cell attachment is increased through nanoscale topographical 
surface features, cell proliferation, cytoskeleton organization, and cell differentiation may 
be subsequently enhanced.[90]  
 For all in vitro experiments, cells were isolated from the bone marrow cavities of 
the femora and tibiae of Sprague Dawley rats, the same rat strain used in subsequent in 
vivo experiments. Using these plastic-adherent bone marrow cells (BMC), an enriched 
source of mesenchymal stem cells that can differentiate towards numerous cell types, 
provides another possible translation between in vitro and in vivo experiments, as the 
femoral marrow cavity is the same location of implant placement. Therefore, the implants 
are in contact with the same “cell environment” used in the in vitro experiment. 
Additionally, the selection of BMC for the in vitro experiment also challenges the 
material, as the cells are not obligated to differentiate into osteoblasts and will only 
differentiate into osteoblasts under specific conditions. 
 
 
 
 
Material contained in this chapter is planned for journal submission. 
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4.2 Experimental Methods 
4.2.1 Bone Marrow Isolation  
 Bone marrow was harvested from the long bones of 14-week old female Sprague 
Dawley rats (SD; Charles River Laboratories, Wilmington, MA) for subsequent cell 
isolation. After euthanizing rats via CO2 asphyxiation, femora and tibiae were aseptically 
harvested and proximal and distal ends of the long bones were removed. Warm, sterile 
phosphate-buffered saline was flushed into the cavities. Whole bone marrow was then 
plated in T-25 culture flasks and cultured at 37oC and 5% CO2 in a sterile, copper-lined 
CO2 incubator. After a 24-hour incubation, non-adherent cells were removed by rinsing 
with warm, sterile saline. The BMC, an enriched source of mesenchymal stem cells 
(MSC) which may differentiate toward numerous cell types, was collected and used for 
all subsequent experiments. 
 
4.2.2 Bone Marrow Cell-Seeding 
 To increase attachment potential, all sample coupons were soaked in fetal bovine 
serum (FBS) for 30 minutes prior to seeding. To seed samples, 40,000 BMC (P2-3) were 
suspended in 50 µL of media (DMEM; Dulbecco’s Modified  Eagle Medium), then drop-
seeded on samples and incubated for 6 hours before adding the remaining 950 µL of 
media and incubating for 20 hours to ensure attachment. ‘Time zero’ commenced after 
final incubation.  
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4.2.3 Cell Attachment and Morphology 
 Early cell attachment and morphology were compared between Aligned TiNT, 
Trabecular TiNT, and Control surfaces, using three samples per group per timepoint. [47] 
Timepoints were defined as 0.5, 2, and 4 hours. At each timepoint, cells were fixed on 
samples with 4% glutaraldehyde, incubated for 30 minutes, then permeabilized with 
methanol and suspended in phosphate buffered saline before staining with either Actin 
Green (Actin Green 488 ReadyProbes Reagent, Life Technologies, Carlsbad, CA) for 
cytoskeleton visualization and morphology (1 drop stain; 40 min incubation) or 4’, 6-
Diamidino-2-Phenylindole, Dihydrochloride (DAPI; Life Technologies, Carlsbad, CA) 
for nucleus visualization (0.5 mL stain; 20 min incubation). Following incubation, 
fluorescence imaging (IX71, Olympus America, Center Valley, PA) at 13 standardized 
regions of interest per coupon was performed, followed by subsequent quantification of 
the total number of adherent cells, cell equivalent diameter, and cell eccentricity (Figure 
4.1).   
 
 
 
 
 
 
 
 
Figure 4.1. Imaging convention for each coupon in the experiment. Regions were chosen 
to reflect the corners (1-4), edges (5-8), central area (9-12), and absolute center (13) of 
each sample. 
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 Because all non-adherent cells were removed prior to imaging, Actin Green and 
DAPI also demonstrated cell adhesion of the surfaces. Environmental scanning electron 
microscopy (SEM; Vega3XMU, Tescan USA, Warrendale, PA) was used to further 
document cell morphology. Total cell number, cell equivalent diameter, and cell 
eccentricity were statistically compared using a one-way analysis of variance (ANOVA) 
model, with a Tukey post-hoc test and α=0.05. 
 
4.2.4 Cell Proliferation and Differentiation 
 Alkaline phosphatase (ALP) and osteocalcin (OC), molecular markers 
characteristic of an osteoblastic phenotype, were assayed to evaluate the propensity of 
BMC cultured on TiNT surfaces to differentiate into osteoblasts. Mature osteoblasts and 
several osteoblast precursor cells abundantly express ALP; however, ALP is also 
expressed by other, non-osteoblast cell types. Therefore, a cell on the bone surface must 
stain positive for ALP to be confirmed as an osteoblast. OC, only expressed in mature 
osteoblasts, has the highest specificity of any marker defining osteoblastic phenotype.[10] 
 ALP activity was measured using a commercially-available colorimetric assay 
(ALP Assay, BioVision, Milpitas, CA). Briefly, after plating in duplicate technical 
replicates, 50 µL of p-nitrophenyl phosphate (pNPP) was added to each well before 
mixing and incubating (60 minutes at 25°C) protected from light. Absorbance was 
measured at 405 nm, relative to pNPP concentration. For experimental samples, 
background absorbance (absorbance of zero standard) was subtracted before calculating 
p-nitrophenol (pNP) concentration, and subsequently, ALP activity, using the equation 
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  ALP Activity (U/mL) = A/V/T      Eq. 1 
 
where A=amount of pNP generated (μmol), V=volume of sample added in the assay well 
(mL), T=reaction time (min). OC expression was measured via sandwich enzyme-linked 
immunosorbent assay (Rat Osteocalcin ELISA, Abbexa, Cambridge, UK). Standards, 
sample, and control (zero) wells, with 50 μL of volume each, were positioned in duplicate 
technical replicates. After incubation (30 min at 37°C), the plate was washed and 
horseradish peroxidase (HRP) conjugated anti-osteocalcin antibody was added to each 
well and incubated (30 minutes at 37°C), before again washing. Tetramethylbenzidine 
(TMB) substrates, 50 μL each, were then added to each well and incubated (15 minutes at 
37°C; protected from light), and absorbance was read at 450 nm. Background absorbance 
(absorbance of zero standard) were subtracted from experimental sample results and OC 
concentration was obtained. ALP activity and OC expression in cell culture supernatant 
was assayed at four time points (3, 7, 14 and 21 days) on six samples per group per time 
point. Statistical significance was assessed using a two-way analysis of variance 
(ANOVA, Factor A: group, Factor B: timepoint) with α=0.05, with a Bonferroni post-hoc 
correction for pairwise comparisons.  
 Quantitative real-time polymerase chain reaction (qPCR) was used to quantify 
messenger RNA-level expression of collagen, type 1, alpha-helix 1 (Col1a1), insulin- like 
growth factor-1 (IGF-1), and osteonectin (ON) gene expression by rat BMC cultured on 
TiNT (Aligned and Trabecular) and Control surfaces. Expression of each gene (e.g. up- 
or down-regulation) via transcription results in protein production through a translation 
process, and these proteins are subsequently transported to the extracellular matrix 
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(ECM). Protein constituency in the ECM is a dynamic process, which then allows the 
ECM of neighboring cells to continuously communicate and adapt.[91] Just as in the 
ALP and OC experiments, qPCR further documents the progression toward osteoblastic 
phenotype and propensity to produce organic matrix leading to bone formation. These 
three genes were selected due to their role in bone formation. Col1a1 is a protein that 
strengthens and supports bone tissue, which is commonly-assayed to quantify Type I 
Collagen, the primary organic constituent of bone. IGF-1 is a protein molecularly-similar 
to insulin that stimulates cell growth and proliferation of many cell types, including 
osteoblasts, while inhibiting apoptosis (cell death). Osteonectin production is a 
phenotypic characteristic of osteoblasts. This protein binds calcium and is secreted by 
osteoblasts during matrix mineralization.  All gene expression was normalized to B-Actin 
(ACTB), which was used in data analysis to normalize variations encountered throughout 
the qPCR process, including sample preparation, RNA isolation, and PCR reaction. At 
each timepoint (3, 7, 14 and 21 days), six samples per group were prepared in triplicate 
technical replicates for each group, according to the previously described methods. At 
experiment endpoint, complementary DNA (cDNA) was synthesized from each sample 
by reverse transcription from each sample (SuperScript 5X VILO Reaction Mix, Life 
Technologies, Carlsbad, CA), followed by preamplification (TaqMan PreAmp Master 
Mix Kit, Life Technologies, Carlsbad, CA, and pooled assay mix) due to the limited 
quantity of cDNA. The preamplification concluded by thermocycling the samples by:  (1) 
hold at 95°C, (2) cycle (n=14) at 95°C for 15 seconds, and (3) cycle (n=14) at 60°C for 4 
minutes. For qPCR analysis, a microcentrifuge tube was prepared for each sample, 
containing primer, cDNA template, gene expression mix, and nuclease free water 
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(TaqMan Gene Expression Master Mix, Life Technologies, Carlsbad, CA). Samples were 
run in triplicate technical replicates and loaded into the qPCR system (Realplex 
Mastercycler System, Eppendorf, Hauppauge, NY) to obtain cycle threshold (CT) for 
each sample, with thermal cycler set to:  (1) hold at 50°C for 2 minutes, (2) hold at 95° 
for 10 minutes, (3) cycle (n=40) at 95°C for 15 seconds, and (4) cycle (n=40) at 60°C for 
1 minute. The CT is the number of cycles required for the generated fluorescent signal to 
cross the fluorescent threshold, a level significantly above background fluorescence. The 
resultant CT value is inversely proportional to the target nucleic acid in the sample. For 
each sample, the three CT values obtained for each gene will be averaged. The average CT 
value of ACTB will then be subtracted from the average CT value of each gene to obtain 
ΔCT . The transformed ΔCT  was calculated by 
 
  Transformed ΔCT  of sample for specified gene = 2(-ΔCT)  Eq. 2 
 
where the transformed ΔCT indicates the up- or down-regulation of the specified gene 
compared to the housekeeping gene, ACTB, on each sample. For each sample, the 
transformed ΔCT  of ACTB was subtracted from the transformed ΔCT  to obtain the ΔΔCT . 
The fold change over Control was calculated by 
 
  Fold change of sample for specified gene = 2(-ΔΔCT)    Eq. 3 
 
 Fold change over Control, representing gene expression of TiNT samples 
normalized to gene expression of Control samples, was averaged for each gene for each 
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group at each timepoint.[92] The fold change over Control was compared between 
groups using a two-way analysis of variance (ANOVA, Factor A: group, Factor B: 
timepoint) with α=0.05, with a Bonferroni post-hoc correction for pairwise comparisons. 
 
4.3 Results 
4.3.1 Cell Attachment and Morphology 
DAPI staining indicated that cells were viable and adhered on both the TiNT and 
Control surfaces at the three early timepoints, 0.5, 2, and 4 hours (Figure 4.2). The total 
number of adherent cells was significantly greater on the TiNT surfaces than Control 
surfaces, demonstrating faster cell attachment on both TiNT surfaces compared to 
Control (Figure 4.3). Specifically, total adherent cells on Trabecular TiNT and Aligned 
TiNT surfaces were significantly greater than Control at 0.5 hours (p=0.014 and p=0.018, 
respectively) and four hours (p=0.008 and p=0.044). Over the 3.5-hour period, the 
number of cells increased on all surfaces, and the total number of adherent cells was 
equivalent or slightly greater on Trabecular TiNT surfaces compared to Aligned TiNT 
surfaces. Analysis of total cell count was unfeasible at later timepoints (3, 7, 14, 21 days) 
due to cell coalescence or superimposition.   
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Figure 4.2. Representative fluorescent images of DAPI-stained surfaces. Aligned TiNT, 
Trabecular TiNT, and Control surfaces at three early timepoints are shown. Timepoints 
were 0.5, 1, and 2 hours. For each substrate, the images are the same sample coupon and 
coupon position (Coupon #2; Position #13—center for all). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Average total cell number on sample surfaces. Total cell number was 
assessed at three early timepoints on TiNT and Control samples. Timepoints:  0.5, 2, and 
4 hours. *Trabecular TiNT vs. Control, p=0.014; **Aligned TiNT vs. Control, p=0.018; 
#Trabecular TiNT vs. Control, p=0.008; ##Aligned TiNT vs. Control, p=0.044. 
*
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 Actin Green staining showed active cell spreading on TiNT and Control surfaces 
at all timepoints (Figure 4.4). At the 2- and 4-hour timepoints, increased spreading was 
observed on TiNT surfaces compared to Control surfaces. Additional imaging via SEM 
showed differential cell morphology patterns as a function of sample topography (Figure 
4.5). On the TiNT surfaces, cells exhibited a globular shape, compared to the elongated, 
fibrillar cell morphology on Control surfaces. 
 
Figure 4.4. Representative fluorescent images of Actin Green-stained surfaces. Aligned 
TiNT, Trabecular TiNT, and Control surfaces at three early timepoints are shown. 
Timepoints were 0.5, 1, 2 hours. For each substrate, the images are the same sample 
coupon and coupon position (Coupon #2; Position #13 for all). 
 
. 
 
 
4 hr 
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0.5 hr 
Aligned TiNT Trabecular TiNT Control 
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Figure 4.5. Representative scanning electron micrographs of sample surfaces. 
Differential cell spreading patterns via extracellular matrix aggregates are illustrated on 
TiNT and Control samples. Pictured are representative images of (A) Aligned TiNT, (B) 
Trabecular TiNT, and (C) surfaces at the 3-day attachment timepoint. 
 
Subsequent analysis of cell morphology images yielded cell equivalent diameter 
and eccentricity (Figure 4.6). Quantification of the cell equivalent diameter indicated that 
BMC on the TiNT surfaces were smaller (in diameter) than BMC on Control surfaces. 
The discrepancy in cell diameter was significant between Trabecular TiNT and Aligned 
TiNT surfaces versus Control at 0.5 hours (p=0.031 and p=0.048, respectively). At the 2-
hour timepoint, there was a significant difference in diameter between only the Aligned 
TiNT and Control surfaces (p=0.008). At 4 hours, the difference in diameter was 
A B 
C 
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significant for both Trabecular TiNT and Aligned TiNT, compared to Control (both 
p=0.003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Average cell equivalent diameter and eccentricity on samples surfaces. 
Average cell equivalent diameter and cell eccentricity were assessed at three early 
timepoints on TiNT and Control samples. Timepoints:  0.5, 2, and 4 hours. For (A) Cell 
Diameter: *Aligned TiNT vs. Control, p=0.048; **Trabecular TiNT vs. Control, 
p=0.031; ^Aligned TiNT vs. Control, p=0.008; #Aligned TiNT vs. Control, p=0.003; 
##Trabecular TiNT vs. Control, p=0.003. Cell For (B) Cell Eccentricity: *Aligned TiNT 
vs. Control, p=0.004; **Trabecular TiNT vs. Control, p=0.007; #Aligned TiNT vs. 
Control, p<0.001; ##Trabecular TiNT vs. Control, p=0.003. 
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Cells on the TiNT surfaces had significantly greater eccentricity than on the 
Control surfaces, with cells on Aligned TiNT demonstrating the greatest eccentricity. At 
0.5 hours, there was a significant difference in eccentricity between the Trabecular TiNT 
and Aligned TiNT, compared to Control (p=0.007 and p=0.004, respectively). There was 
a significant difference between both the Trabecular TiNT and Aligned TiNT groups 
versus Control again at 2 hours (p=0.003 and p<0.001, respectively). There were no 
significant differences in eccentricity between groups at the 4-hour timepoint. 
  
4.3.2 Cell Proliferation and Differentiation 
 Aligned TiNT, Trabecular TiNT, and Control surfaces were compared to one 
another and Control samples with respect to ALP activity and OC expression by cultured 
rat marrow-derived BMC (Figure 4.7). ALP and osteocalcin were expressed throughout 
the experiment, demonstrating the differentiation of the BMC to osteoblastic phenotype. 
After a large, initial secretion of ALP and OC at Day 3, expression on the Aligned TiNT 
was approximately constant for the remainder of the timepoints, yet always greater than 
Control. Trabecular TiNT surfaces exhibited greater ALP activity and OC expression 
than Control at Day 3, then decreased expression at Day 7 before progressively 
increasing for the remainder of the experiment.  
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Figure 4.7. Osteocalcin expression and alkaline phosphatase (ALP) activity on sample 
surfaces. Presented are Aligned TiNT, Trabecular TiNT, and Control surfaces at four 
timepoints. Timepoints: 3, 7, 14, and 21 days. For (A) osteocalcin, n=6/group; *p=0.005 
vs. Control, ** p=0.003 vs. Control, # p=0.039 vs. Control, *** p=0.009 vs. Control, ## 
p<0.001 vs. Control. For (B) alkaline phosphatase, n=6/group; *p=0.014 vs. Control, ** 
p=0.004 vs. Control, #p=0.037 vs. Control, ***p=0.001 vs. Control, ##p<0.001 vs. 
Control. 
 
 After statistically comparing OC expression between groups via two-way 
ANOVA, significance was found between Aligned TiNT vs, Control at Day 3 (p=0.005), 
Aligned TiNT vs. Control and Trabecular TiNT vs. Control at Day 14 (p=0.003 and 
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p=0.039, respectively) as well as Aligned TiNT vs. Control and Trabecular TiNT vs. 
Control at Day 21 (p=0.009 and p<0.001, respectively). Statistical analysis of ALP 
activity between groups using a two-way ANOVA mirrored the osteocalcin analysis, 
showing significance of Aligned TiNT vs. Control at Day 3 (p=0.014), Aligned TiNT vs. 
Control and Trabecular TiNT vs. Control at Day 14 (p=0.004 and p=0.037, respectively) 
as well as Aligned TiNT vs. Control and Trabecular TiNT vs. Control at Day 21 
(p=0.001 and p<0.001, respectively).  
 qPCR was performed to quantify Col1a1, IGF-1, ON gene expression of BMC 
cultured on Aligned TiNT, Trabecular TiNT, and Control surfaces at the same four 
timepoints. For each sample, three CT values were obtained for each gene and averaged 
and all gene expression was normalized to the ACTB housekeeping gene (Figure 4.8). 
Data was log-transformed, and groups were then statistically compared using a two-way 
ANOVA to assess fold change over Control data. No significant differences were found 
between the TiNT groups at each timepoint for any of the genes. For Col1a1, there were 
significant differences between fold change of Trabecular TiNT surfaces over Control 
between the 3-day and 1-week timepoints (p=0.004) as well as between the 1-week and 
3-week timepoints (p=0.004). For osteonectin, there was a significant difference between 
fold change of Trabecular TiNT surfaces over Control between the 3-day and 1-week 
timepoints (p=0.046). 
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Figure 4.8. Gene expression on TiNT and Control surfaces. Gene expression is presented 
as a function of fold change of Aligned TiNT and Trabecular TiNT over Control at four 
timepoints. Genes assayed were (A) Col1a1, (B) IGF-1, and (C) osteonectin. 
A 
B 
C 
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4.4 Discussion and Conclusions 
 We evaluated the biocompatibility of Aligned and Trabecular TiNT surface via an 
in vitro study focused on cell morphological and attachment behavior as well as 
osteoconductive properties focused on the characterization of osteoblastic differentiation 
of BMC cultured on TiNT surfaces by assaying ALP activity, OC expression, and gene 
expression.  
 In vitro testing, using widely-used analysis techniques, of BMC seeded on TiNT 
and Control surfaces was performed.[47, 81, 93] DAPI and Actin Green staining 
demonstrated cell attachment and spreading from 0.5 hours through 21 days on all 
surfaces, an indication of the suitable environment of both TiNT surfaces and Control. 
Total cell counts were greater on TiNT surfaces compared to unetched Controls at the 
three early timepoints, which corresponds with current trends in the literature.[36, 68, 94] 
We also observed that the diameter of BMC on TiNT surfaces was smaller compared to 
cells seeded onto Controls, and cells on TiNT surfaces were more eccentric than cells on 
Controls. These data correspond with SEM imaging of attached BMC, which showed 
rounded cell morphology on TiNT surfaces and fibrillar-shaped cells on Control surfaces. 
The diameter, eccentricity, and imaging findings may be an indication that the cells are 
developing in different planes on the TiNT surfaces compared to Controls. Shokuhfar 
sectioned TiNT arrays seeded with osteoblasts (MC3T3-E1; mouse preosteoblasts) and 
observed cell attachment on nanotube arrays as well as cell filopodia stretching 
downward into the hollow portion of individual nanotubes.[74] Therefore, these 
differences in cell morphologic behavior between groups may be explained by the BMC 
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interaction with TiNT surfaces, as the BMC extend into nanotubes and voids within the 
array, instead of across the top of the surface. 
 ALP and OC assays, indicators of activity signaling a shift of BMC toward an 
osteoblastic phenotype, showed that both ALP activity and OC expression were 
signficantly greater on TiNT surfaces at multiple timepoints, compared to Control as well 
as indirectly indicated cell viability. These results corresponded with a study by Popat, et 
al. that showed increased ALP activity of titania nanotube surfaces seeded with MSC 
compared to unmodified titanium, which was indicative of cell adhesion, proliferation, 
and differentiation to an osteoblastic phenotype.[68] Zhao, et al. described increased ALP 
activity in titania nanotube surfaces etched at two different voltages (5V and 20V), 
compared to smooth and acid-etched microstructured surfaces, after seeding samples with 
primary rat calvarial osteoblast cells.[81] When comparing titania nanotubes ranging 
from 30 nm to 100 nm diameter cultured with mouse preosteoblast cells (MC3T3-E1), 
Brammer, et al. measured significantly increased ALP activity on all titania nanotube 
surfaces, compared to flat titanium control samples, which increased proportionally with 
nanotube diameter.[78] Differential ALP activity and OC expression patterns were found 
between the Aligned TiNT and Trabecular TiNT surfaces. ALP activity and OC 
expression was approximately constant on the Aligned TiNT surfaces after Day 3, yet 
progressively increased on Trabecular TiNT surfaces from Days 7 through 21. This may 
indicate that the cells require additional time to attach and proliferate on Trabecular 
TiNT, compared to Aligned TiNT surfaces, through the bone-like morphology of 
Trabecular TiNT may promote differentiation as OC expression and ALP activity 
increased throughout the later timepoints. Brammer, et al. discussed the limited 
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adherence of osteoblasts on titania nanotubes with 100 nm diameter, compared to the 
abundant cell adhesion on 30 nm-diameter nanotubes. As a result of the empty pores 
between the larger diameter arrays, osteoblasts initially attached to the top walls/features 
and then must extend filopodia to protein-deposited surfaces, resulting in greater cell 
elongation on larger diameter nanotube surfaces; however, over time, the surfaces with 
100 nm diameter nanotubes produced the greatest ALP activity.[78] Gene expression 
analysis, focusing on three specific genes related to bone formation, demonstrated  
increased fold-change of TiNT surfaces over Control at multiple timepoints. Pozio, et al. 
also observed an upregulation of Col1a1 after a 14-day culture of human osteoblasts on 
titania nanotube surfaces, which later downregulated at a 30-day timepoint.[95]  
 Our study limitations involved difficulties with staining the TiNT surfaces, 
especially at timepoints greater than 4 hours. Because of the nanotopography and voids, 
which were ideal for cell attachment, stain penetration of the cells was complicated and 
incomplete. Also, in the qPCR analysis, we encountered difficulty removing the BMC 
seeded on TiNT samples. Despite adding additional time for Trypsin penetration and 
scraping samples, we were unable to effectively remove the cells, which subsequently 
required additional pre-amplification and introduced variability. 
 BMC were harvested from the intramedullary canals of long bones, including 
femora, of the same SD rat strain used in the in vivo study. In effect, the implant in our 
subsequent in vivo studies was then placed in the same location and environment as the 
cell harvest (Chapters 5 and 6). The titania nanotube surfaces were also challenged via 
the selection of BMC for the in vitro experiment, as the cells are not obligated to 
differentiate into osteoblasts and will only differentiate into osteoblasts under specific 
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conditions. Additionally, SD rats, an outbred rat strain was used to approximate the 
differential osseointegrative potential experienced in the human population. Our results 
indicate inherent cell attachment, cell viability, cell differentiation to an osteoblastic 
phenotype by 3 days, and cell proliferation over the course of the 21-day experiment. The 
in vitro results provided justification to pursue an in vivo study. 
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Chapter 5: 
In Vivo Assessment of Biocompatibility Titania Nanotube Surfaces in a 
Rat Model of Intramedullary Fixation 
 
5.1 Introduction 
Using a clinically-relevant model of long-term femoral intramedullary implant in 
a rat to simulate joint arthroplasty, TiNT-etched implants were compared to unetched 
controls by assessing longitudinal animal weights, remote organ weights, metal ion levels 
in remote organs and whole blood, hematology, and undecalcified histology.[96] We 
hypothesize that TiNT surfaces will demonstrate equivalent biocompatible and non-toxic 
results, equivalent to unmodified titanium alloy substrate surfaces. 
 
5.2 Experimental Methods 
 After preparing titanium alloy Kirschner wires (K-wire; Modern Grinding, Port 
Washington, WI; material=Ti-6Al-4V ELI Hard, diameter=1.25 mm, single trocar tip for 
insertion) according to the methods in Chapter 3, Aligned TiNT-etched, Trabecular 
TiNT-etched, or unetched titanium K-wire implants (n=6 per group) were inserted 
retrograde into the femoral intramedullary canals of SD rats for a single, long-term 
endpoint of 12 weeks.[97-99] Three naïve/nonoperative animals were housed for the 
same duration, in order to establish baseline characteristics. SD rats, an outbred strain, 
were selected to approximate differential outcomes in the human population. Throughout 
the study, the rats received daily veterinary care to identify complications and were  
 
Material contained in this chapter is planned for journal submission. 
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weighed weekly. At endpoint, hematologic, metal ion, and histologic analyses were  
performed. 
 
5.2.1 Implantation Procedure 
 Under an IACUC-approved protocol (Beaumont AL-14-04; MTU 680637), 14-
week old, female SD rats were anesthetized [induction: intraperitoneal injection of 
ketamine (75-100 mg/kg) and xylazine (3-5 mg/kg); maintenance: inhaled isoflurane (1-
2%)] and placed supine on a sterile, heated operating table. Each animal received 
unilateral femoral implants via retrograde insertion. Placing the knee in 45 degrees of 
flexion, a lateral parapatellar skin incision was created. Returning the limb to extension, 
the incision was extended over the femorotibial (knee) joint. The dissection was carried 
down through retinaculum and joint capsule, which were incised in line with the skin 
incision, allowed access to the distal femur. Adequate soft tissue off the patella was left 
to facilitate capsular repair. With the limb again in maximum flexion, the patella was 
retracted medially, and a shallow pilot hole was drilled in the intercondylar groove. 
Subsequently, the K-wire was inserted at the center of the intercondylar notch. With the 
aid of fluoroscopy, the K-wire was advanced to the distal end of the greater trochanter. 
The distal end of the K-wire was cut and tamped to avoid a proud implant (Figure 5.1). 
TiNT morphology was randomized just prior to surgery by nonoperative staff.   
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Figure 5.1. Radiographs following bilateral Kirschner wire implantation. Representative (A) 
anteroposterior (A) and lateral (B) views from Rat 25 are shown. 
A 
B 
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5.2.2 General Health Assessment 
 All rats were evaluated daily for clinical signs of complications and overall 
health, including pain level, activity level, and food/water consumption. Rats were 
weighed preoperatively and weekly throughout the experiment. At endpoint, remote 
organs (i.e. spleen, liver, lungs, kidneys, brain) were collected and weighed, as another 
assessment of animal health. A one-way ANOVA model was used to compare 
longitudinal animal weights and endpoint organ weights between treatment groups, with 
α=0.05. 
 
5.2.3 Hematologic Analysis 
At endpoint, each anesthetized rat underwent antemortem cardiac puncture to 
collect blood for hematologic analyses to quantify the following thirteen parameters 
associated with either systemic inflammation/infection or anemia status: white blood cell 
count (WBC), lymphocyte concentration (Lymph), monocyte concentration (Mono), 
granulocyte concentration (Gran), hematocrit (HCT), mean cell volume of red blood cells 
(MCV), red blood cell distribution width (RDWa), hemoglobin concentration (Hgb), 
mean cell hemoglobin concentration (MCHC), mean cell hemoglobin (MCH), red blood 
cell count (RBC), total platelet count (PLT), mean and platelet volume (MPV) 
(HemaTrue Hematology Analyzer, Heska, Loveland, CO). Blood was collected in 
vacutainer tubes with EDTA and immediately processed. A one-way ANOVA model was 
used to compare hematologic parameters between treatment groups, with α=0.05. 
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5.2.4 Metal Ion Analysis 
 Inductively coupled plasma mass spectrometry (ICP-MS; HP 4500 Series, Agilent 
Technologies, Santa Clara, CA) was used to measure the titanium, aluminum, and 
vanadium concentrations in each remote organ and a whole blood sample from each 
animal. ICP-MS calibration was performed using both ASTM standards of each target 
element as well as non-implanted samples of the K-wires from each testing condition. 
After the animals were euthanized, the remote organs (i.e. spleen, liver, lungs, kidneys, 
brain) were harvested, weighed, and then stored in ultra-low leachable sample tubes at 
4°C. To dissolve any metal present in the organ tissues into an aqueous solution, samples 
were digested by adding a purified solution of HNO3, HCl, H2O2, and water directly into 
sample tubes. Sample tubes were then heated at 95°C for 2 hours. After setting the final 
digested tissue volume at 40 mL per sample, the homogenized samples were diluted 10-
fold and analyzed for titanium, aluminum, and vanadium concentration (ng of metal/g of 
sample). Samples were analyzed in tandem with a laboratory reagent blank and duplicate 
laboratory fortified blanks to quantify background metal levels as well as procedure 
accuracy and precision, respectively. A one-way ANOVA model was used to compare 
metal ion levels between treatment groups, with α=0.05. 
 
5.2.5 Undecalcified Histologic Analysis 
At study endpoint, implanted femora were also harvested for undecalcified histologic 
analysis. Femora from each animal were stripped of soft tissues and placed in formalin 
for 96 hours, followed by three rinses in phosphate buffered saline, and ethanol storage to 
prepare for histologic processing. Femora were subsequently embedded in methyl 
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methacrylate, then ground and polished longitudinally to the approximate center of the 
implant, followed by cutting and applying one 5 μm thick section to a slide. Each slide 
was stained with Stevenel’s Blue and van Gieson picrofuchsin (SBVG) for visualization 
of fibrous and mineralized tissue as well as the presence of immune-related cellular 
activity. SBVG is a widely-used stain to assess bone formation, due to visualization of 
both mature bone and osteoid as well as fibrous tissue, which may signify inferior 
osseointegration and/or increased inflammatory response, especially at the bone-implant 
interface.[100-102] Stained sections were manually scanned at a magnification of 20x 
(90i, Nikon Instruments, Inc., Melville, NY) to facilitate both high-magnification and 
whole-mount analyses. Three 20x regions of interest (ROI) per location (i.e. distal, 
midshaft, proximal) per section were captured. Within each ROI, five cell types were 
identified:  foreign body giant (FBG)/multinucleated cell, granulocyte (non-neutrophilic, 
including eosinophils and basophils), neutrophil, monocyte, and lymphocyte. Cell 
constituents within each ROI were then graded on a scale of 0 to 2, with 0=no cells, 
1=cells comprising ≥25% of field, and 2=cells comprising ≥50% of field. For 
FBG/multinucleated or granulocyte, a Grade 2 was defined as three or more cells per 
field. Grades were statistically compared between TiNT groups and Control, using a 
Mann-Whitney Rank Sum Test, with α=0.05. 
 
5.3 Results 
Over the 12-week study, animals gained an average of 148 g, with Control 
animals gaining the most weight on average (179 g) and Trabecular TiNT animals 
gaining the least on average (118 g) (Figure 5.2A). No animals lost more than 10% body 
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weight, our institutional trigger for intervention. At Week 9, the Aligned TiNT group 
weighed significantly more than the Trabecular TiNT group (p=0.013), and at Week 11, 
the Control group weighed significant more than the Trabecular TiNT group (p=0.023). 
There were no significant differences at any other weekly time points. Mass of the spleen, 
brain, kidneys, lungs, and liver were obtained, and there were no significant differences 
between any groups for the specimens (Figure 5.2B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Animal body (weekly) and remote organ weights (endpoint) were measured. 
These weights are one means to assess general health. Average animal (A) body weight 
and (B) organ weight per group over the 12-week study are presented.*Week 9:  Aligned 
TiNT vs. Trabecular TiNT, p=0.013; **Week 13:  Trabecular TiNT vs. Control, p=0.023.    
B 
A 
* 
** 
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 Hematologic analysis was performed, and no significant associations were found 
between any groups for any parameters (Tables 5.1 and 5.2). 
 
Table 5.1.  Hematologic analysis of white blood cell function at endpoint. Average values 
are shown for each treatment group.* 
Group WBC Lymph Mono Gran Lymph%  Mono%  Gran%  
Aligned 
TiNT 
9.5 
(2.7) 
7.3 
(1.8) 
0.4 
(0.2) 
1.7 
(0.7) 
77.9   
(2.7) 
3.9  
(1.3) 
18.2 
(2.6) 
Trabecular 
TiNT 
8.02 
(3.5) 
6.2 
(2.7) 
0.3 
(0.1) 
1.5 
(0.8) 
77.9    
(3.9) 
3.3  
(1.6) 
18.8 
(2.9) 
Control 8.9 
(2.2) 
7.0 
(1.6) 
0.3 
(0.1) 
1.5 
(0.6) 
79.7    
(2.5) 
3.1  
(0.8) 
17.3 
(2.2) 
Naïve 11.0 
(6.1) 
8.4 
(3.9) 
0.5 
(0.4) 
2.1 
(1.8) 
79.1   
(6.1) 
3.1  
(0.8) 
17.8 
(5.3) 
  * Standard deviation listed in parentheses; WBC=white blood cell count,      
  Lymph=lymphocyte concentration, Mono=monocyte concentration, Gran=    
  granulocyte concentration 
 
Table 5.2.  Hematologic analysis of red blood cell function at endpoint. Average values 
are shown for each treatment group.* 
Group HCT MCV RDWa RDW%  Hgb MCHC MCH RBC PLT MPV 
Aligned 
TiNT 
40.1 
(3.2) 
49.7 
(1.1) 
32.8 
(1.0) 
16.4 
(0.5) 
15.3 
(1.2) 
38.3 
(0.5) 
19.0 
(0.3) 
8.1 
(0.6) 
318.7 
(149.4) 
6.4 
(0.8) 
Trabecular 
TiNT 
38.3 
(1.5) 
50.0 
(0.9) 
32.9 
(0.7) 
16.4 
(0.6) 
14.6 
(0.4) 
38.3 
(0.6) 
19.1 
(0.5) 
7.7 
(0.4) 
275.8 
(151.6) 
6.7 
(0.6) 
Control 
40.1 
(3.5) 
50.9 
(1.2) 
34.0 
(1.6) 
16.4 
(0.4) 
15.1 
(1.2) 
37.7 
(0.5) 
19.1 
(0.4) 
7.9 
(0.6) 
335.0 
(89.7) 
6.4 
(0.5) 
Naïve 
41.4 
(2.8) 
50.6 
(0.8) 
33.7 
(0.2) 
16.5 
(0.4) 
15.6 
(1.1) 
37.7 
(0.2) 
19.1 
(0.3) 
8.2 
(0.5) 
305.7 
(93.5) 
6.1 
(0.8) 
* Standard deviation listed in parentheses; HCT=hematocrit, MCV=mean cell volume of 
red blood cells, RDWa=red blood cell distribution width, Hgb=hemoglobin 
concentration, MCHC=mean cell hemoglobin concentration, MCH=mean cell 
hemoglobin, RBC=red blood cell count, PLT=total platelet count, MPV=mean and 
platelet volume 
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 Titanium, aluminum, and vanadium levels of each implant type (e.g. Aligned 
TiNT, Trabecular TiNT, Control) were analyzed to quantify the effect of the etching 
process on chemistry (Table 5.3). Compared to Control, Aligned TiNT and Trabecular 
TiNT demonstrated greater aluminum and vanadium content and lower titanium content, 
by wt%.  
 
Table 5.3.  Comparison of alloy composition between groups. Data was quantified via 
inductively coupled plasma mass spectrometry. 
Group Element Composition (wt% ) 
Aligned TiNT 
Titanium 86.036 
Aluminum 7.032 
Vanadium 6.933 
Trabecular TiNT 
Titanium 86.744 
Aluminum 6.958 
Vanadium 6.298 
Control 
Titanium 89.238 
Aluminum 6.455 
Vanadium 4.308 
 
 After weighing each organ, metal concentration in each organ and whole blood 
were assessed. Aluminum levels in the lungs were significantly greater in the Trabecular 
TiNT group compared to Control (p=0.022). No other organs exhibited significantly 
increased titanium, aluminum, or vanadium levels compared to Control (Figure 5.3). 
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Figure 5.3. Metal ion concentration in remote organs and whole blood for each group. of 
The three metals assayed were (A) aluminum, (B) titanium, and (C) vanadium, the 
constituents of the alloy used throughout the study. (WB=whole blood). *Aluminum:  
Trabecular TiNT vs. Control, p=0.022. 
A 
B 
C 
* 
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 Histologic analysis demonstrated a lack of inflammatory infiltrate in proximity to 
the nails within the intramedullary space, for all groups (Table 5.4). There were 
significantly less eosinophils/basophils and neutrophils in the Distal ROI of the femora 
implanted with Trabecular TiNT-etched implants (p=0.040 and p=0.019, respectively). In 
the Midshaft ROI, there were significantly less foreign body giant/multinucleated cells 
and neutrophils in the Aligned TiNT group (p=0.039 and p=0.019, respectively). There 
were no observed necrotic or cytotoxic events observed within the marrow cavity of any 
of the animals (Figure 5.4). 
  
Table 5.4.  Average histologic grade for three regions of interest in each group.* 
ROI Group 
Foreign Body 
Giant/ 
Multinucleated 
Granulocyte Neutrophil Monocyte Lymphocyte 
Distal 
Trabecular TiNT 0.833 (1.0) 0.056 (0.0) 0.722 (1.0) 0.778 (1.0) 1.111 (1.0) 
Aligned TiNT 0.722 (1.0) 0.222 (0.0) 1.056 (1.0) 0.778 (1.0) 1.056 (1.0) 
Control 0.556 (0.5) 0.333 (0.0) 1.000 (1.0) 0.722 (1.0) 1.222 (1.0) 
Midshaft 
Trabecular TiNT 0.500 (0.5) 0.611 (1.0) 1.000 (1.0) 0.556 (1.0) 1.222 (1.0) 
Aligned TiNT 0.389 (0.0) 0.833 (1.0) 0.722 (1.0) 0.667 (1.0) 1.056 (1.0) 
Control 0.778 (1.0) 0.722 (1.0) 1.000 (1.0) 0.722 (1.0) 1.222 (1.0) 
Proximal 
Trabecular TiNT 0.833 (1.0) 0.611 (1.0) 0.944 (1.0) 0.778 (1.0) 1.389 (1.0) 
Aligned TiNT 0.722 (1.0) 0.444 (0.0) 1.056 (1.0) 0.889 (1.0) 1.278 (1.0) 
Control 0.722 (1.0) 0.722 (1.0) 1.000 (1.0) 0.833 (1.0) 1.444 (1.0) 
*Median values listed in parentheses; Statistically significant values bolded. Cell  
constituents within each ROI were then graded on a scale of 0 to 2, with 0=no cells, 
1=cells comprising ≥25% of field, and 2=cells comprising ≥50% of field. For 
FBG/multinucleated or granulocyte, a Grade 2 was defined as three or more cells per 
field. 
 
 
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Histologic sections and regions of interest of representative femora. 
Representative images from longitudinal histologic sections of Aligned TiNT (A), and 
Trabecular TiNT (B), and Control (C) groups are illustrated. 
 
A 
B 
C 
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5.4 Discussion and Conclusions 
We evaluated the biocompatibility of Aligned and Trabecular TiNT surfaces via a 
clinically-relevant in vivo study of biologic response to implant materials. The in vivo 
study included multiple characterization methods, including a general health assessment 
(e.g. body weight) as well as hematologic, metal ion, and histologic analyses.  
In this study, no interventions were required for disease or weight loss 
(institutional policy allows ≤20% weight loss, based on initial body weight), throughout 
the experiment. There were several significant differences in body weight between 
groups at two weeks during the experiment, however, the body weights recovered and 
were not an established trend. At endpoint, remote organ masses were compared between 
groups, and these also showed no significant difference.   
When metal ion concentration was assessed in remote organ and whole blood 
samples, aluminum levels were significantly increased in the lungs of the rats implanted 
with Trabecular TiNT-etched K-wires compared to Controls. No other organs or whole 
blood samples showed significantly elevated metal levels, when the experimental groups 
were compared to Control. A study of intraarticular injection of TiO2 nanoparticles (45 
nm average diameter; 0.2, 2, 20 mg/kg TiO2 in suspension) into rat knee joints showed 
nanoparticle migration to remote organs as well as pathologic changes in the heart, lung, 
liver, and knee at 7 days post-injection.[103] Although our study showed metal particle 
concentration in remote organs via ICP-MS and did not histologically-assess remote 
organs, we theorize that the amount of TiO2 particulate debris shed in the rat femora was 
less than 0.2 mg/kg.  
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At study endpoint, no hematologic markers of white and red blood cell function, 
which would signal systemic inflammation-, infection-, or anemia-related complications, 
were significantly elevated in the experimental groups compared to Control. Histologic 
analysis showed several significant differences in cell populations between the TiNT 
groups and Control, with less foreign body giant/multinucleated, eosinophil/basophil, and 
neutrophil cell activity in TiNT-implanted femora than Control. There were no significant 
differences in monocyte and lymphocyte activity between the TiNT groups and Control. 
In in vitro and in vivo studies of vascular toxicity, Bayat, et al. established that 
titania nanotubes with 30nm diameter as well as ultra-small TiO2 nanoparticles (1-3 nm) 
were not cytotoxic and nanoparticles did not possess oxidative potential.[104] In vivo 
studies in rat models have also shown that TiO2 nanoparticles are not genotoxic.[105, 
106] Neacsu, et al. showed that after seeding murine macrophages onto TiNT and 
unetched titania surfaces under pro-inflammatory and standard conditions, inflammatory 
activity related to cytokine and chemokine gene expression, foreign body giant cell 
production, and nitric oxide release all decreased on TiNT surfaces but not on unetched 
controls. The authors suggested that the TiNT surfaces may regulate macrophage 
response thereby diminishing the overall inflammatory cascade,[107] a comparable 
finding in a study where leukocytes were seeded on TiNT surfaces.[108] Another study 
showed increased adsorption of blood serum protein, platelet adhesion and activation, 
and clotting of whole blood as well as no evidence of monocyte activation and cytokine 
secretion on TiNT surfaces versus control.[109] 
Previous reports have demonstrated the biocompatibility of TiNT surfaces and 
correspond with our findings that TiNT surfaces do not initiate systemic effects in a 
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clinically-relevant, in vivo model of simulated joint arthroplasty, which would impact 
body and organ weights, hematologic parameters, and result in observable deficits and/or 
complications in the study animals.              
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Chapter 6: 
In Vivo Assessment of Osseointegration of Titania Nanotube Surfaces in 
a Rat Model of Intramedullary Fixation 
 
 
6.1 Introduction 
 Titanium alloy Kirschner wires (K-wire; Modern Grinding, Port Washington, WI; 
material=Ti-6Al-4V ELI Hard, diameter=1.25 mm, single trocar tip for insertion) were 
etched with Aligned or Trabecular TiNT and inserted retrograde into the femoral 
intramedullary canals of SD rats.[97-99] This outbred strain was selected to approximate 
differential osseointegrative capabilities and outcomes in the human population. Two 
endpoints, 4 weeks and 12 weeks, were included to compare the rate of periprosthetic 
bone formation and osseointegration. Multiple characterization methods, including 
biomechanical testing, microcomputed tomography (μCT), backscattered electron 
imaging (BEI), and undecalcified histology, were performed. For all data, the ratio 
between the experimental (Aligned TiNT or Trabecular TiNT) and Control femora were 
calculated for each bilateral pair and averaged for each morphology at each endpoint. 
 
6.2 Experimental Methods 
6.2.1 Implantation Procedure 
 Under an IACUC-approved protocol (Beaumont AL-14-04; MTU 680637), K-
wire implants were implanted, as described in Chapter 5. One limb received an unetched  
titanium K-wire, while the other limb received either an Aligned TiNT- or Trabecular 
 
Material contained in this chapter is planned for journal submission. 
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TiNT-etched K-wire. TiNT morphology was randomized just prior to surgery by 
nonoperative staff, with eight animals per morphology per endpoint. Following surgeries, 
animals were randomized to endpoint and characterization cohorts. Characterization 
cohorts were “Imaging” (μCT, backscattered imaging, and histology; three animals per 
morphology per endpoint) and “Biomechanics” (five animals per morphology per 
endpoint). 
 
6.2.2 Imaging Analysis 
 For animals randomized to the Imaging cohort (μCT, BEI, and histology), femora 
were harvested at each endpoint, stripped of extraneous tissues, and placed in 10% 
neutral buffered formalin for a minimum of 96 hours to allow for formalin penetration 
and tissue fixation (n=3 paired femora per group per timepoint). 
 
6.2.2.1 Microcomputed Tomography Analysis 
 After 96 hours, each femur was rinsed with saline three times in a 24-hour period, 
then wrapped in saline-soaked towel and placed in a “wet” sample tube for μCT scanning 
(μCT-40, Scanco USA, Wayne, PA). Scans were performed using a voltage of 70 kVp, 
current of 114 µA and a 300 ms integration time, yielding a 16 µm isotropic voxel size. 
Two scan regions, 190 slices of the midshaft (i.e. Midshaft volume of interest) and 127 
slices just proximal to the physis (i.e. Distal volume of interest) were selected. All 
analyses were performed with the Scanco onboard evaluation software.[98, 110, 111] 
Alignment of each sample in the z-axis using the center of the implant as a reference was 
performed, followed by reimporting of revised stacks. Contours were generated for each 
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volume of interest (VOI) by applying contours to the first and last valid slices and 
interpolating between these slices, with correction as needed. For the Midshaft VOI, a 
freeform outline was applied circumferentially to the interface of the cortical shell and 
intramedullary canal, and then iterated forward from first to last slice. For the Distal VOI, 
an ellipse (110 pixels x 110 pixels) was applied to each slice. A segmentation process 
was performed to determine lower thresholds for the implant and bone as well as dilation 
distance, using four specimens per endpoint (n=2 with TiNT morphology, n=2 Control) 
(Figure 6.1).  
 The average of the lower threshold values determined in the segmentation process 
as well as the dilation distance that minimized beam hardening artifact were applied to all 
specimens in the final evaluation process.[110] Total bone volume (TBV) and bone 
volume per total volume (BV/TV; bone volume fraction) per slice and per VOI were 
obtained. Histomorphometric parameters, quantitative measures of de novo bone quality, 
were also collected, including connectivity density (Conn.D; measure of trabeculae 
connectivity normalized by total volume, 1/mm3), structure model index (SMI; descriptor 
of trabeculae structure and presented as absolute value in this data set, 0=parallel plates 
and 3=cylindrical rods), trabecular number (Tb.N; average number of trabeculae per 
length, 1/mm), trabecular thickness (Tb.Th; average thickness of trabeculae, mm), 
trabecular separation (Tb.Sp; average distance between trabeculae, mm), volume mineral 
density (VMD; mineralization density of bone tissue only, mg/cm3 of hydroxyapatite), 
and bone mineral density (BMD; mineralization density of entire volume, both bone and 
non-bone tissue, mg/cm3 of hydroxyapatite).[110]  
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Figure 6.1. Image processing of μCT scans for Distal and Midshaft volumes of interest 
(VOIs). Distal and Midshaft VOIs are presented in the left and right columns, 
respectively. (A,B) Contouring, (C,D) segmentation of implant and bone, (E,F) assigning 
dilation distance, (G,H) two-dimensional visualization of bone-implant contact, and (I,J) 
three-dimensional reconstruction with bone-implant contact are shown. Femora 21R and 
38L were used for Distal and Midshaft VOIs, respectively. 
A B 
C D 
E F 
G H 
I J 
77 
 
6.2.2.2 Backscattered Electron Analysis 
 After μCT, specimens were placed in 70% ethanol for BEI and histologic 
analysis.[112] Femora were subsequently embedded in methyl methacrylate, then ground 
and polished longitudinally to the approximate center of the implant. These longitudinal 
sections were marked at 5 mm and 15 mm proximal to the femoral notch to guide Distal 
and Midshaft region of interest (ROI) selection, respectively, for imaging in an 
environmental scanning electron microscope (SEM; Vega3XMU, Tescan USA, 
Warrendale, PA) using a lanthanum hexaboride (LaB6) filament and the onboard 
backscattered electron detector. Imaging was performed with a 20 kV accelerating 
voltage and 15 mm working distance, under low pressure (10 Pa) to minimize sample 
charging. Identical magnification, contrast/brightness and beam intensity were used to 
ensure consistency in field of view size and grayscale values between specimens. Images 
were then imported into evaluation software (ImageJ, National Institutes of Health, 
Bethesda, MD) for quantification of bone at the implant interface. For the Midshaft ROI, 
quantification of bone contact at the interface furthest from the cortical shell was 
obtained, while the Distal ROI was quantified on both interfaces of the implant. A 
segmentation process using four specimens per endpoint (n=2 with each TiNT 
morphology, n=2 Control) was completed to establish minimum and maximum 
thresholds for bone. The average of these respective threshold values was applied to all 
specimens in the final imaging analysis. In the Midshaft ROI, three zones were defined in 
the portion of the intramedullary canal furthest from the cortical shell at one, two, and 
three pixels away from the implant. Six zones were placed in the Distal ROI at one, two, 
and three pixels from the implant interface, with three zones on each side of the implant 
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interface. After entering threshold values, the particle (bone) count, average particle 
(bone) size, total particle (bone) area, and percentage of particle (bone) area for each zone 
was obtained. Additionally, the fraction of bone-implant contact across the entire image 
was calculated from line profiles for each ROI at one, two, and three pixels from the 
implant interface. The ratio between the paired experimental and Control femora of each 
parameter was calculated for each bilateral pair and averaged for each morphology at 
each endpoint. 
 
6.2.3 Undecalcified Histologic Analysis 
 At the conclusion of BEI, the blocks were prepared for final undecalcified 
histologic processing. Each block was gently ground and polished, before cutting and 
applying one 5 μm thick section to a slide. Each slide was then stained with Stevenel’s 
Blue and van Gieson picrofuchsin (SBVG) for visualization of mature bone (red), osteoid 
(green or gray/green), and collagen/fibrous tissue (blue) at the bone-implant interface. 
SBVG is a widely-used stain to assess bone formation, due to visualization of both 
mature bone and osteoid as well as fibrous tissue, which may signify biocompatibility 
issues, inferior osseointegration, and/or increased inflammatory response, especially at 
the bone-implant interface.[100-102] Stained sections were manually scanned at a 
magnification of 20x (90i, Nikon Instruments, Inc., Melville, NY) to facilitate both high-
magnification and whole-mount analyses. Manual analysis was performed to quantify 
periprosthetic bone formation by measuring and then dividing the length of each segment 
of bone-implant contact along the entire length of the implant and the entire length of the 
implant to calculate the bone-implant contact fraction. Ratios between the experimental 
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and Control femora of bone-implant contact fraction were calculated, and averaged for 
each morphology at each endpoint. 
 
6.2.4 Biomechanical Analysis 
 At experiment endpoint, the femora of animals randomized to biomechanical 
testing were dissected from each limb, stripped of extraneous soft tissues, wrapped in 
saline-soaked gauze, and stored at -20°C until testing. Femora were thawed overnight at 2 
to 4°C, then immersed in phosphate buffered saline for 2 hours to rehydrate. After towel-
drying the femora, a rotary tool fitted with a grinding attachment (Dremel, Mount 
Prospect, IL) was used to remove the proximal third of the femora to expose 4 to 5 mm of 
the K-wire. Using an electromechanically-actuated materials testing system (Insight 150, 
MTS, Eden Prairie, MN) with a custom-designed and fabricated fixture, bone-implant 
strength was assessed via a wire pull-out test. For each femur, the K-wire was secured in 
a drill chuck, which was anchored to the fixture and testing frame, while the distal 
portion of the femora was fixed in polyester resin (Bondo, 3M, St. Paul, Minnesota) 
within the fixture and attached to the base of the frame (Figure 6.2).  
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Figure 6.2. Custom-designed and fabricated fixture for biomechanical testing. 
Photograph was obtained just prior to wire pull-out. 
 
 For each test, the program ramped to 10 N at 0.25 mm/s, held for 20 s (pre-load), 
and then loaded to failure at 2 mm/min and the force required to remove the implant from 
the bone was recorded. Data collected during the test, at a sampling rate of 100 Hz, was 
used to create axial force-displacement curves. From the resultant curves, strength of 
fixation was calculated according to the equation 
 
        Eq. 4 
 
where σu=strength of fixation (MPa), Fmax=maximum pull-out force (to loosen implant) 
(N), D=implant diameter (mm), and H=bone length after dissection (mm). This equation 
accounted for individual post-dissection bone length (H), which therefore addressed 
differences in pull-out force due to bone-implant fixation as a function of the length of 
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each bone.[99] Maximum failure load and strength of fixation data were compared 
between groups using a two-way analysis of variance (ANOVA, Factor A: group, Factor 
B: endpoint), with a Tukey post-hoc correction and α=0.05. Several K-wires were imaged 
after biomechanical testing to document bone ongrowth. 
 
6.3 Results 
 To assess intramedullary fixation, K-wires etched with Aligned TiNT or 
Trabecular TiNT were compared to an internal Control, an unetched K-wire.  
 μCT, backscattered electron imaging, and histology were performed on each 
femora after harvesting at the specified endpoint for animals randomized to the Imaging 
cohort. For μCT, a segmentation process was performed to determine lower thresholds 
for the implant and bone as well as dilation distances, using four specimens per endpoint. 
The lower thresholds obtained during the segmentation process were averaged and used 
in the final evaluations. For the Distal VOI, the implant threshold was 722 Hounsfield 
units and the bone threshold was 363 Hounsfield units. For the Midshaft VOI, the implant 
threshold was 791 Hounsfield units and the bone threshold was 347 Hounsfield units. 
Hounsfield units are a measure of the radiodensity, or X-ray attenuation, of the implant 
and bone tissue relative to water. Materials and tissues that absorb more X-rays than 
water, including bone, have greater Hounsfield units.[113] Optimal dilation distance of 3 
to 6 voxels from the outside diameter of the K-wire was determined, after using a post-
processing algorithm to minimize beam hardening artifacts.[112, 114]  
 After segmentation, the onboard bone-implant contact program was used to 
calculate the total bone volume and bone volume fraction in each two-dimensional slice, 
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and subsequently per VOI. The ratio between the experimental (Aligned TiNT or 
Trabecular TiNT) and Control femora were calculated for each bilateral pair, and 
averaged for each morphology at each endpoint (Figures 6.3 and 6.4). Histomorphometric 
analysis was also performed to assess bone quality characteristics of the periprosthetic 
bone (Table 6.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Average total bone volume and bone volume fraction in the Distal volume of 
interest (VOI). Data was collected and processed via μCT. The (A) total bone volume and 
(B) bone volume fraction of the Distal volume of interest are presented as ratios between 
TiNT morphology and Control. 
 
B 
A 
83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4. Average total bone volume and bone volume fraction in the Midshaft volume 
of interest (VOI). Data was collected and processed via μCT. The (A) total bone volume 
and (B) bone volume fraction of the Midshaft volume of interest are presented as ratios 
between TiNT morphology and Control. 
 
 
 
 
 
A 
B 
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Table 6.1.  Average histomorphometric parameters of femora. Data is presented as 
ratios of TiNT-implanted femora versus internal Controls in Distal and Midshaft volumes 
of interest. Data was collected and processed via µCT.* 
Group VOI 
Endpoint 
(week) 
Conn.D SMI** Tb.N Tb.Th Tb.Sp VMD BMD 
Trabecular  
TiNT/              
Control 
Distal 
4 
1.24          
(0.58) 
1.18        
(1.23) 
0.97 
(0.06) 
1.00 
(0.05) 
1.23 
(0.42) 
0.97 
(0.05) 
1.00 
(0.02) 
12 
1.13        
(0.51) 
1.10       
(0.71) 
0.96 
(0.05) 
1.03 
(0.11) 
1.02 
(0.01) 
1.04 
(0.16) 
1.00 
(0.02) 
Midshaft 
4 
1.27        
(0.67) 
1.02       
(0.32) 
0.84 
(0.57) 
0.98 
(0.22) 
1.73 
(1.25) 
0.90 
(0.29) 
0.99 
(0.09) 
12 
2.10        
(1.44) 
0.77       
(0.08) 
1.55 
(0.22) 
1.28 
(0.04) 
0.65 
(0.07) 
1.40 
(0.24) 
0.97 
(0.02) 
Aligned         
TiNT/               
Control 
Distal 
4 
1.51        
(0.57) 
17.53    
(25.93) 
1.08 
(0.15) 
1.05 
(0.22) 
0.89 
(0.14) 
1.09 
(0.12) 
1.01 
(0.01) 
12 
1.10         
(0.43) 
1.02      
(1.44) 
1.01 
(0.10) 
1.23 
(0.42) 
0.95 
(0.20) 
1.21 
(0.33) 
1.02 
(0.04) 
Midshaft 
4 
1.44          
(0.49) 
0.85      
(0.24) 
1.19 
(0.11) 
1.07 
(0.27) 
0.85 
(0.05) 
1.03 
(0.09) 
0.95 
(0.01) 
12 
71.29    
(120.88) 
0.92            
(0.69) 
1.22 
(0.28) 
1.97 
(1.33) 
0.89 
(0.18) 
1.46 
(0.38) 
0.98 
(0.07) 
*Standard deviation listed in parentheses, **Absolute value of the SMI presented. 
Conn.D=connectivity density, SMI=structure model index, Tb.N=trabecular number, 
Tb.Th=trabecular thickness, Tb.Sp=trabecular separation, VMD=volume mineral density, 
BMD=bone mineral density 
 
 For BEI analysis of Distal and Midshaft regions of interest (ROI), images were 
imported into evaluation software. For the Distal ROI, the threshold minimum and 
maximum values were 29096 and 38555 pixels, while the threshold values for the 
Midshaft ROI were 28479 and 26883 pixels. Ratios between bone area and bone-implant 
contact fraction (average percentage of bone-implant contact) at each ROI were 
calculated (Figure 6.5 and Table 6.2, respectively). Line profiles showing the highly 
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variable differences in bone-implant contact between the TiNT-implanted and Controls 
were also plotted (Figures 6.6 and 6.7). 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 6.5. Bone area fraction in the Midshaft and Distal regions of interest. Data is 
presented as ratios between TiNT-implanted femora and respective internal Controls in 
the (A) Midshaft and (B) Distal regions of interest at 4- and 12-week endpoints. 
 
 
 
 
 
 
A 
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Table 6.2.  Average bone-implant contact fraction ratios. Data is presented for the Distal 
and Midshaft regions of interest.* 
 
 
 
 
 
 
 
    * Standard deviation listed in parentheses 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 6.6. Line profiles in the Midshaft region of interest. Profiles presented are 
internal Controls versus (A) Aligned TiNT at 4 weeks, (B) Trabecular TiNT at 4 weeks, 
(C) Aligned TiNT at 12 weeks, and (D) Trabecular TiNT at 12 weeks. 
 
 
Region of 
Interest 
Endpoint 
(week) 
Trabecular TiNT/Control Aligned TiNT/Control 
Midshaft 
4 0.93 (0.19) 5.01 (8.65) 
12 0.21 (0.18) 0.90 (0.42) 
Distal 
4 1.68 (1.74) 1.06 (0.07) 
12 1.42 (0.12) 1.29 (1.02) 
A B 
C D 
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Figure 6.7. Line profiles in the Distal region of interest. Profiles presented are internal 
Controls versus (A) Aligned TiNT at 4 weeks, (B) Trabecular TiNT at 4 weeks, (C) 
Aligned TiNT at 12 weeks, and (D) Trabecular TiNT at 12 weeks. 
 
 Following BEI, each longitudinal section was stained with SBVG (Figures 6.8 
and 6.9). Ratios of bone-implant contact between TiNT and Control femora were 
calculated, showing increased bone-implant contact in femora with TiNT implants (Table 
6.3). At 12 weeks, both Aligned and Trabecular TiNT implants established approximately 
1.5 times greater bone-implant contact than Control-implanted femora. 
 
 
 
 
A B 
C D 
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Figure 6.8. Representative images of full-mount undecalcified histologic sections. Images 
shown are from (A) internal Control of Aligned TiNT, (B) Aligned TiNT, (C) internal 
Control of Trabecular TiNT, and (D) Trabecular TiNT. (SBVG; 20x magnification) 
 
 
 
 
 
B A C 
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Figure 6.9. Representative images of regions of interest from histologic sections. Images 
shown are from full-mount undecalcified histologic sections of (A) Aligned TiNT, (B) 
internal Control of Aligned TiNT, (C) Trabecular TiNT, and (D) internal Control of 
Trabecular TiNT. (SBVG; 50x magnification) 
 
Table 6.3.  Average bone-implant contact ratios. Bone-implant contact was measured on 
full-mount histologic sections at two endpoints. 
 
 
 
 
 
 
 
 
 
        * Standard deviation listed in parentheses 
  
 Each femora randomized to biomechanics testing was subjected to a tensile test to 
facilitate K-wire pull-out (Figure 6.10). Strength of fixation and maximum failure load 
Group 
Endpoint 
(week) 
Average Ratio of Bone-Implant Contact 
(TiNT/Control)* 
Aligned TiNT 
4 2.95 (2.73) 
12 1.58 (0.24) 
Trabecular TiNT 
4 1.10 (0.67) 
12 1.50 (0.55) 
A 
B 
C 
D 
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were then calculated for each femora, then averaged according to morphology and 
endpoint (Figure 6.11). However, at the 4-week Trabecular TiNT group, only three 
matched pairs were tested due to one failure at the time of femora preparation for testing 
(i.e. K-wire dislodged from femur) and one in vivo fracture discovered at endpoint 
dissection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10. Representative force-displacement curves obtained from biomechanical 
testing. Biomechanical testing was performed via wire pull-out. Force-displacement 
curves are shown for an (A) Aligned TiNT versus internal Control to Aligned TiNT (Rat 
36) and a (B) Trabecular TiNT versus internal Control to Trabecular TiNT (Rat 26). 
 
A 
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Figure 6.11. Average maximum failure load and strength of fixation at two endpoints. 
The average (A) maximum failure load and (B) strength of fixation data are presented as 
ratios between TiNT morphology and Controls.  
 
 At the 4-week endpoint, the average ultimate load of Aligned TiNT-implanted 
femora was 114 N (range, 59 to 165) and the Trabecular TiNT group was 148 N (range, 
79 to 231), compared to the respective internal Controls 41 N (range, 23 to 65) and 38 N 
(range, 12 to 76). The difference in maximum failure load was significant for the Aligned 
TiNT versus internal Control groups (p=0.016) as well as the Trabecular TiNT versus 
internal Control groups (p=0.025) at 4 weeks. At 12 weeks, femora in the Aligned TiNT 
A 
B 
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and Trabecular TiNT groups achieved average maximum failure loads of 208 N (range, 
152 to 263) and 179 N (range, 108 to 206), with comparative Controls demonstrating 
loads of 140 N (range, 23 to 218) and 139 N (range, 81 to 199), respectively.  
 The ratio of strength of fixation between experimental TiNT and internal Control 
femora was also calculated for each pair, then averaged by morphology and endpoint. 
The strength of fixation of the Trabecular TiNT group was 3.7 and 1.3 times greater than 
Control at 4 and 12 weeks, respectively. In the Aligned TiNT group, strength of fixation 
was 2.8 and 1.6 times greater than Control at 4 and 12 weeks, respectively. Strength of 
fixation was significantly greater for the Aligned TiNT group, compared to internal 
Controls, at the 4-week endpoint (p=0.016). 
 Several K-wires were imaged with SEM after biomechanical testing. Imaging 
showed several regions of the K-wires encased in bone after 4 weeks of implantation 
(Figure 6.12). One region imaged demonstrated mature bone cleaved from the cortical 
bone in the intramedullary canal during testing (Figure 6.12A), indicating that failure 
occurred at the bone-bone interface and not due to the nanotube surface disuniting from 
the implant. A second region showed the K-wire copiously coated in bone, with visible 
lacuna signifying organized bone tissue development (Figure 6.12B). Additionally, bony 
protrusions in this region were likely attached to the cortical bone prior to mechanical 
testing. A high magnification image of the second region shows the nanotube surface still 
coated in adsorbed protein after mechanical testing (Figure 6.12C). 
 
93 
 
 
 
 
 
 
 
 
 
Figure 6.12. Trabecular TiNT Kirschner wire imaged after biomechanical testing. These 
implants (pilot group) were implanted for 4 weeks. Scanning micrograph images show 
(A,B) implants coated in bone and (C) adsorbed protein. 
 
6.4 Discussion and Conclusions 
 In vivo osseointegration was evaluated via a rat intramedullary implant model, 
using biomechanics, undecalcified histology, microcomputed tomography (μCT) and 
backscattered electron imaging (BEI) techniques. These studies were designed to test our 
A B 
C 
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hypotheses that TiNT surfaces would improve osseointegration at both early and late 
timepoints, due to increased osteoblast attachment and bone mineralization. 
The model used in this work, intramedullary fixation in a rat, is a common model to 
assess osseointegration after different treatments (e.g. implant technologies, systemic or 
local applications of compounds).[97-99] All study animals tolerated the surgical 
procedure, gained weight, and were weight-bearing (immediately postoperative) through 
the respective 4- or 12-week postoperative period. 
 Various characterization methods were used to evaluate the osseointegrative 
properties of the implanted femora at early and late, 4- and 12-week, endpoints. Three 
matched pairs (TiNT and internal Control) femora were subjected to μCT, BEI, and 
histologic analyses. μCT evaluation showed both total bone volume and bone volume 
fraction of TiNT-implanted femora increased at greater rates than internal Controls from 
the 4- to 12-week endpoints in the Distal and Midshaft VOIs, on average. In the Distal 
VOI, Aligned TiNT implants demonstrated increased bone formation compared to 
Control, with a ratio of 1.3. Bone formation was nearly equivalent for Trabecular TiNT 
and Control surfaces. In the Midshaft VOI, the total bone volume and bone volume 
fraction ratios ranged from 1.5 (Aligned TiNT) to 2.1 (Trabecular TiNT) at the 4-week 
endpoint and 2.6 (Trabecular TiNT) to 16.8 (Aligned TiNT) at the 12-week endpoint, 
indicating enhanced bone formation in the midshaft for both TiNT surfaces. Aligned 
TiNT ratios at 12 weeks were skewed by a single matched pair, due to exceptional bone 
formation in the TiNT-implanted femora compared to the internal Control. Dang, et al. 
assessed differences between three types of screw implants:  titania nanotube-etched (at 
10 V and 40 V), titania nanotube + strontium-etched, and grit-blasted titanium (control), 
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which were implanted into the intercondylar notches of SD rats for 12 weeks. The 
average bone volume fraction of the titania nanotube-etched screws ranged from 
approximately 0.17 to 0.20 for the two sample types, compared to our results of 0.40 for 
Trabecular TiNT and 0.52 for Aligned TiNT implants in the Distal VOI at the 12-week 
endpoint.[115] Similarly, a study of implants fabricated via etching titania nanotubes 
onto resorbable blast media demonstrated significantly increased bone volume at 12 
weeks versus controls (machined and titania nanotube-etched machined surfaces), after 
implantation into canine humeri.[116]  
 Regarding μCT-based histomorphometric data, Ban, et al. reported significantly 
increased BMD in the etched titania nanotubes on resorbable blast media samples.[116] 
Our study showed approximately equivalent BMD in both the Aligned TiNT and 
Trabecular TiNT implants, compared to Controls; however, the VMD of the Aligned 
TiNT and Trabecular TiNT groups was greater than Controls (range, 1.04 to 1.46 times) 
at the 12-week endpoint in both the Distal and Midshaft VOIs, indicating increased 
density of the bone tissue compared to Controls. At both endpoints and VOIs, Conn.D 
was greater in all TiNT femora compared to Controls (range, 1.13 to 71.29 times). In 
both TiNT and Control femora VOIs and endpoints, SMI suggested a more plate-like 
structure, as demonstrated by the SMI (range, 0.400 to 1.268). In the Distal VOIs, Tb.N 
remained approximately equivalent between both TiNT morphologies and Controls at 
both endpoints, but was greater than Controls in the Midshaft VOI and also increased 
from the 4-week to 12-week endpoint. At a 12-week endpoint, Dang, et al. reported a 
Tb.N value of approximately 4/mm in the distal femora of SD rats implanted with titania 
nanotube-etched implants, compared to 7.3/mm and 7.8/mm in our Trabecular TiNT and 
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Aligned TiNT groups, respectively.[115] Both TiNT groups and Controls had equivalent 
Tb.Th in both VOIs at the 4-week endpoint, and then all values increased to 1.03 to 1.97 
times greater than Control at the 12-week endpoint. Specifically, Tb.Th at 12 weeks were 
0.085 mm and 0.096 mm for Trabecular TiNT and Aligned TiNT groups, respectively, 
compared to values ranging between 0.04 and 0.05 µm in a similar study.[115] In 
general, Tb.Sp was greater than Controls in the Trabecular TiNT group and less than 
Controls in the Aligned TiNT group, at both endpoints and VOIs. Dang, et al. 
demonstrated less Tb.Sp, approximately 0.2 µm, while our data showed values of 0.147 
mm in the Trabecular TiNT group and 0.143 mm in the Aligned TiNT group.[115] 
 BEI showed that the bone-implant contact fractions were 1.4 and 1.3 times greater 
in the Trabecular TiNT and Aligned TiNT implants than their internal Controls in the 
Distal ROI, respectively. However, BEI results were inconsistent in the midshaft, as only 
one longitudinal section was analyzed, compared to three-dimensional assessment 
capabilities around the entire implant in µCT analysis. Similar to our BEI findings in the 
distal region of interest, a study comparing titania nanotube-etched and titania grit-blasted 
screws in a rabbit model of distal femoral condyle implantation indicated titania nanotube 
implants had 1.1 times more de novo bone formation, on average, than grit-blasted 
samples at a six-week endpoint.[85] Histologic analysis assessed the bone-implant 
contact along the full length of the implant (except the unetched trocar tip) and 
approximately agreed with the BEI analysis of the distal region at the 12-week endpoint, 
with bone-implant contract ratios of approximately 1.5 for both TiNT implants versus 
internal Controls. Longitudinal sections from titania nanotube-etched implants exhibited 
a narrow curtain of bone (predominately mature), which extended along large sections of 
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the bone-implant interface, which was not observed in Control sections. Sul also 
observed a thin border of bone tissue surrounding titania nanotube-etched screws within 
the marrow cavity, yet, this border of bone tissue was not adjacent to grit-blasted 
implants.[85] von Wilmowsky, et al. also reported greater bone-implant contact of titania 
nanotube-etched rod-shaped implants versus unmodified, internal controls at 14-day and 
90-day endpoints, in a pig model of frontal bone (skull) implantation.[88]  
 Five matched pairs of femora underwent biomechanical testing via a wire pull-out 
test to determine strength of fixation. In both TiNT morphology groups at both endpoints, 
the TiNT-etched implants demonstrated greater strength of fixation compared to internal 
Controls, between 1.3 and 3.7 times, on average. Also, the average strength of fixation 
increased for both TiNT groups, by 94 N for the Aligned TiNT group and 32 N for the 
Trabecular TiNT group, from the 4- to 12-week endpoints. At the 4-week endpoint, the 
maximum failure loads of the Aligned TiNT (p=0.016) and Trabecular TiNT (p=0.025) 
were significantly greater than internal Controls, respectively. Similarly, strength of 
fixation in the Aligned TiNT group was significantly greater than controls (p=0.016). 
Dang, et al. performed tensile testing to test the pull-out strength of the 12 mm long 
implants placed in the intercondylar notch of the femur for 12 weeks, which showed the 
two titania nanotube-etched groups had significantly greater failure loads than 
controls.[115] Using their reported load data and implant dimensions, the average 
strength of fixation for their nanotube-etched groups produced via 10 V and 40 V were 
approximately 0.32 MPa and 0.85 MPa, respectively. On average, the strength of fixation 
of the Trabecular TiNT and Aligned TiNT groups measured 1.87 MPa and 2.29 MPa at a 
12-week endpoint. Several other in vivo studies reported greater failure loads in titania 
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nanotube-etched samples versus controls, however comparing their results to our study is 
complicated by implant treatments, implant location and/or animal type.[72, 86] SEM 
imaging demonstrated titania nanotube post-test survivability, as Friedrich, et al. and von 
Wilmowsky, et al. showed in simulated bone material (Sawbones) and porcine 
models.[88, 117] 
  Our study was limited primarily by sample size, with n=3 matched pairs in the 
“Imaging” group and n=5 matched pairs in the “Biomechanics” group. Although our 
results are unpowered, consistent trends were demonstrated throughout the 
characterization process, indicating the positive influence of the TiNT surfaces on 
osseointegrative properties.  
 We presented an in vivo study comparing two TiNT morphologies to an 
unmodified control. In a clinically-relevant model of femoral intramedullary fixation, 
characterization of harvested femora demonstrated greater bone formation and quality as 
well as strength of fixation in femora implanted with TiNT-etched implants versus 
control-implanted femora. 
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Chapter 7: 
Future Work 
 
 
7.1 Introduction 
 Our hope is that the previously described studies advance the research of titanium 
nanotube (TiNT) surfaces for biomedical applications. Certainly, there are numerous 
continuations of this work. In the sections below, planned and proposed research 
concepts are presented. 
 
7.2 Proposed Concept 1:  Local Delivery of SDF-1β via Titania Nanotube Surfaces 
During primary or revision orthopaedic surgical procedures, the periprosthetic 
environment is exposed and primed for local delivery of pharmacologic agents and small 
molecules, which may modulate various biologic responses, including inflammation, 
foreign body response, and osteogenesis. Drug delivery localized to the affected tissues 
precludes deleterious effects of systemic drug delivery. For instance, systemic delivery of 
etidronic acid, a bisphosphonate used to reduce loss of bone mass and bone resorption by 
promoting osteoclast apoptosis, may cause fevers, transient hematologic changes, and 
irritative reactions (of skin, peritoneum, and pericardium) as well as uveitis, scleritis, and 
phlebitis.[118-120] The morphology of TiNT surfaces, with voids and hollow structures 
thereby increasing total surface area, is ideal for drug loading and delivery. Numerous 
groups have drug-loaded TiNT surfaces via immersion, film deposition, intercalation, or 
pipetting techniques.[121-126] 
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Our proposed research will evaluate the drug delivery potential of these two 
morphologies of titania nanotube surfaces prepared via functionalization of heparin 
binding domains. Our work will use a drug release kinetics experiment and in vivo (rat) 
model of femoral intramedullary fixation (simulated femoral stem or stemmed distal 
femoral condyle, as described in Chapters 5 and 6) with biomechanical, histologic, and 
μCT characterization to assess the influence of TiNT structure and drug delivery on de 
novo bone formation and bone-implant stability at a single (12-week) timepoint. 
 As described, our previous work has demonstrated promising osteogenic effects 
of both Aligned TiNT and Trabecular TiNT surfaces on marrow-derived cells. We 
subsequently translated these in vitro results to an in vivo study, where μCT scans 
performed at 4- and 12-week postoperative endpoints demonstrated increased bone 
formation in TiNT implants, compared to unmodified titanium implants. In the proposed 
research, we will use Aligned TiNT and Trabecular TiNT implants to deliver stromal 
cell-derived factor 1 (SDF-1β), which is highly chemotactic for mesenchymal stem 
cells.[127] We hypothesize that SDF-1β delivery will result in enhanced recruitment of 
stem cells and subsequent new bone formation by the recruited cells.  
 
7.2.1 Specific Aims 
 In this study, we plan to first evaluate the drug loading and release potential of the 
protein SDF-1β from two morphologies of titania nanotube surfaces and as-received 
(unmodified) titanium. A surface chemistry-based approach to drug loading will be used 
in an effort to achieve sustained drug release. These results will then be translated into an 
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in vivo study to assess differences in bone formation between protein-loaded and 
unloaded Aligned TiNT- and Trabecular TiNT-etched implants. 
 
Aim 1:  Demonstrate extended release of SDF-1β from TiNT surfaces, prepared with 
Aligned TiNT and Trabecular TiNT morphologies and functionalized with heparin-
binding domains. 
 
Aim 2:  Investigate the effect of heparin-mediated SDF-1β delivery from TiNT surfaces 
on in vivo bone formation, using microcomputed tomography (µCT), backscattered 
imaging, biomechanical testing and undecalcified histology. 
 
7.2.2 Study Design 
7.2.2.1 Aim 1: Heparin-Dopamine Functionalization of TiNT Implants and SDF-1β 
Release Kinetics  
 
 Work in Aim 1 will focus on functionalization of TiNT surfaces to bind SDF-1β 
as well as characterization of resultant release kinetics. Two TiNT surfaces, Aligned 
TiNT and Trabecular TiNT, will be compared to as-received (unmodified) titanium 
(Control). Samples (coupons and Kirschner wires) will be prepared as described in 
Chapter 3. 
 To promote the attachment of SDF-1β to the implant materials, all surfaces will 
be functionalized with a heparin-dopamine (Hep-DOPA) conjugate (5mg of heparin/mL 
solution). SDF-1β, like many cytokines and chemokines, possesses a heparin-binding 
domain. The dopamine component of the Hep-DOPA conjugate will anchor heparin 
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molecules to the metal-oxide surface, thus promoting the electrostatic deposition of SDF-
1β.[128] The Hep-DOPA conjugation technique for heparin immobilization is well-
established on metal and metal-oxide surfaces.[129, 130] Confirmation of Hep-DOPA 
conjugation will be confirmed via an established toluidine blue staining method as well 
as x-ray photoelectron spectroscopy (XPS).[131] Kim, et al. observed a decrease in 
nitrogen content when heparin was engrafted onto amine-treated titania surfaces.[132] In 
a separate study, Lui, et al. showed increased sulfur content when functionalizing 
surfaces with Hep-DOPA.[133] 
 To immobilize SDF-1β (positive charge) onto the surfaces, Hep-DOPA-
functionalized TiNT samples will be immersed in 2-(N-morpholino)ethanesulfonic acid 
(MES)-buffered SDF1-β (1mg/mL) then shaken overnight, washed dried at 50°C. 
Prepared samples will then be immersed in individual wells filled with 1000µL of 
phosphate buffered saline and bovine serum albumin (PBS+BSA) solution at 37oC, in 
order to study the release kinetics of SDF-1β from Hep-DOPA-modified Aligned TiNT, 
Trabecular TiNT and as-received titanium specimens. Every 24 hours, 100µL of 
PBS+BSA will be removed and refreshed. At designated timepoints (24 hours…3, 5, 7, 
14, 21, 28, 35, 49, 63, 77, and 91 days), 100µL of supernatant will be extracted for 
quantification of SDF-1β via ELISA (Rat Stromal Cell Derived Factor 1 ELISA Kit, 
MyBiosource, San Diego, CA). Our group has also developed a HPLC-based method for 
detection of chemokines in release media, which will be used if immunoenzymatic 
methods fail. 
 
103 
 
7.2.2.2 Aim 2: Comparison of In Vivo Osteogenicity of SDF-1β-functionalized TiNT 
Implants  
  
 Following confirmation of successful functionalization and release, we will begin 
in vivo testing detailed in Aim 2. Using titanium as well as stainless steel implants, our 
group has performed more than 100 implantations of intramedullary implants (Kirschner 
wires; K-wires) in rat femora, thereby optimizing both surgical technique as well as µCT- 
and histology-based characterization of periprosthetic bone formation in this challenging 
model. Ti-6Al-4V K-wires with a 1.25 mm diameter will be prepared with either an 
Aligned TiNT or Trabecular TiNT surface (Aim 1). Also, half of the implants will be 
loaded with SDF-1β using the Hep-DOPA conjugation technique (Aim 1). Following 
preparation of the implants, 16 Sprague Dawley rats will undergo a bilateral implantation 
procedure to insert K-wires into the intramedullary canal of the femur, as described in 
Chapters 5 and 6. This model is widely-used to assess periprosthetic bone formation 
around implants to be used as structural elements in total joint arthroplasty 
procedures.[48, 98, 99, 134] Rats will be randomized to receive either Aligned TiNT or 
Trabecular TiNT K-wires, with both femora receiving K-wires with the same 
morphology. Each femur will receive one SDF-1β-functionalized implant and one 
unloaded TiNT implant, which will also be randomized (Table 7.1).  
 
Table 7.1.  Distribution of animals and limbs in each group. Planned characterization 
methods are also listed. 
Group Number of 
Animals 
Number of 
Limbs 
μCT Histology Biomechanics 
Aligned TiNT 8     
+ SDF-1β  8 8 3 5 
- SDF-1β  8 8 3 5 
Trabecular TiNT 8     
+ SDF-1β  8 8 3 5 
- SDF-1β  8 8 3 5 
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 Periprosthetic bone formation in all limbs will be characterized via serial µCT 
imaging at 3, 6 and 12 weeks postoperative. Resultant DICOM images will be analyzed 
via on-board software scripts to obtain histomorphometric properties of de novo bone, 
including total tissue volume (TV), total bone volume (BV), bone volume fraction 
(BV/TV) as well as volume and bone mineral density (VMD; BMD). At the 12 week 
endpoint, animals will be euthanized and femora excised. Limbs randomized to histologic 
characterization of bone formation will be prepared as described in Chapter 6. 
Backscattered electron imaging will be performed on all ground sections with an 
environmental scanning electron microscope, in order to quantify the degree of 
mineralization at the bone-implant interface as well as the bone-implant contact area. 
Following imaging, methyl-methacrylate-embedded specimens will undergo microtomy 
to yield thin, 5 mm sections which will be stained with Stevenel’s Blue and von Gieson 
picrofuschin (SBVG). Stained sections will be digitally scanned at 40x magnification and 
resultant digital images will be analyzed by a blinded grader will be employed to quantify 
the number of osteoblasts and osteoclasts per high-powered field. Limbs randomized to 
biomechanical analysis will be wrapped in saline-soaked gauze and frozen at -20°C until 
analysis.[135] The strength of the bone-implant interface will be characterized via 
biomechanical pull-out testing performed on a materials loading frame, as described in 
Chapter 6.  
 
7.2.3 Anticipated Outcomes 
 SDF-1β is a protein chemotactic to mesenchymal stem cells (MSCs). These 
proteins have not previously been loaded onto TiNT surfaces. We expect to generate data 
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showing that Hep-DOPA conjugation results in sustained versus burst delivery of SDF-
1β from TiNT surfaces compared to unmodified control implants. Because of the 
increased surface area associated with Trabecular TiNT surfaces, we anticipate increased 
SDF-1β loading on Trabecular TiNT surfaces compared to Aligned TiNT surfaces. 
Similarly, we anticipate increased bone formation on Trabecular TiNT + SDF-1β 
surfaces in vivo due to the higher drug loading. 
 
7.2.4 Study Status 
 This study has been funded by a Beaumont Health Seed Grant and is in progress. 
All pilot work has been completed, with toluidine blue staining and X-ray photoelectron 
spectroscopy (XPS, Kratos Axis Ultra, Kratos Analytical, Manchester, United Kingdom) 
confirming Hep-DOPA functionalization of TiNT surfaces (Figures 7.1 and 7.2).   
 
 
 
 
 
 
 
 
Figure 7.1. Toluidine blue staining for heparin content on sample coupons. Staining 
showed greater heparin content on heparin-dopamine-functionalized coupons than 
unfunctionalized coupons. [Groups: Control, Annealed Aligned TiNT (Align-A), 
Unannealed Aligned TiNT (Align-UA), Annealed Trabecular TiNT (Trab-A), Unannealed 
Trabecular TiNT (Trab-UA)]. Values were corrected (i.e. baseline absorbance 
subtracted) based on calculated standards. 
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Figure 7.2. Spectra obtained from X-ray photoelectron spectroscopy of sample coupons. 
Samples analyzed were heparin-dopamine-functionalized annealed, unannealed, and 
control titania and titania nanotube-etched surfaces. The spectra demonstrated a 
decrease in nitrogen and sulfur contents on heparin-dopamine-functionalized annealed, 
unannealed, and control titania and titania nanotube-etched surfaces. 
 
 Toluidine blue staining showed greater heparin content on coupons functionalized 
with Hep-DOPA than on unfunctionalized coupons. On the functionalized surfaces, 
unannealed coupons contained a greater amount of bound heparin than annealed coupons. 
XPS demonstrated decreased nitrogen and sulfur contents on surfaces with bound 
heparin, further confirmation of effective Hep-DOPA functionalization. Based on these 
results, the remaining experiments will be conducted with unannealed titania nanotube 
surfaces. 
 A pilot experiment was performed to immobilize three dosages of SDF-1β onto 
functionalized K-wires, in order to establish attachment behavior (Table 7.2). Results 
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showed greater than 99% attachment of SDF-1β on all surfaces at all dosages at time 
zero. 
 
Table 7.2.  SDF-1β attachment on Kirschner wires. Wires were prepared with 
unannealed titania nanotube and Control surfaces at three dosages. 
Group Immobilized SDF-1β (ng) SDF-1β Attachment (% ) 
Trabecular TiNT 
50 99.9893 
100 99.9909 
500 99.9986 
Aligned TiNT 
50 99.9882 
100 99.9948 
500 99.9978 
Control 
50 99.9899 
100 99.9937 
500 99.9991 
 
 A pilot release experiment was conducted to trial the proposed methods. Again, 
three dosages were examined. Samples were immersed in a PBS+BSA solution, and the 
supernatant was analyzed at four timepoints (Figure 7.3). All samples showed similar 
release profiles, with total released quantity of SDF-1β averaging 0.0413 ng (range, 
0.0365 to 0.0487) for all groups and dosages. 
 Next steps include finishing the drug release kinetics experiments, which began 
early June 2016, and K-wire implantation procedures, which will be performed in July 
2016 (surgeries boarded:  7/5/16, 7/716, 7/12/16, 7/14/16). The final experimental 
endpoint is scheduled for September/October 2016.  
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Figure 7.3. Release profiles of SDF-1β from Kirschner wires. Wires were unannealed 
and functionalized with heparin-dopamine before attaching SDF-1β. Attachment was 
assayed at five timepoints:  0, 24, 48, 72, and 144 hours. Three dosages of SDF-1β were 
evaluated, including (A) 50ng, (B) 100ng, and (C) 500ng. 
C 
B 
A 
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7.3 Proposed Concept 2:  Assessing Biocompatibility of Titania Nanotubes via Murine 
Air Pouch Model 
 
 A 2004 study by Ren, et al. first described an in vivo model of orthopaedic wear-
debris associated osteolysis using ultra-high molecular weight polyethylene (UHMWPE) 
particles.[136] In the model, air pouches were produced on the backs of BALB/c mice 
(female, 8-10 weeks old) by sterile air injection. Six days after pouch formation, femora 
and calvaria from littermates were harvested to use as donor bone tissue. Either femora or 
calvaria tissue were placed into air pouches and sutured closed. The following day, 
UHMWPE particles were injected into the pouch to initiate the wear-debris induced 
inflammatory cascade leading to periprosthetic osteolysis [experimental groups:  5 mg of 
particles suspended in 0.5 mL of fetal bovine serum/phosphate buffered saline; control 
group:  0.5 mL of fetal bovine serum/phosphate buffered saline (FBS/PBS)] until 
experiment endpoints at 2, 7, and 14 days after particle injection. At endpoint, pouch 
membrane, bone tissue (femora or calvaria), and fluid from pouch were collected for 
analysis.  
 To assess the effect of UHMWPE particles on bone and surrounding (pouch) 
tissue, various characterization techniques were used. First, the thickness and total cell 
counts of the pouches were measured, showing differences between experimental and 
group groups. Tartrate-resistant acid phosphatase (TRAP) staining of implanted bone 
tissue for osteoclastic activity showed intense staining in both the pouch membranes and 
implanted calvaria. Clusters of osteoclasts were observed at the interface between tissue 
and UHMWPE particles. Polymerase chain reaction (PCR) analysis confirmed 
upregulation of capthesin K (CK) in tissues from experimenta l groups. Histologic 
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analysis also demonstrated differences between experimental and control groups. In 
UHMWPE-treated pouches, hematoxylin and eosin (H&E) staining showed bone erosion 
and Masson’s trichrome staining showed bone collagen loss, compared to control 
pouches. The study indicated donor calvaria tissue implantation was more consistent than 
femora tissue, as the calvaria could be trimmed to 4 mm diameter and calvarial caps are 
associated with less affixed tissue.  
 The model continues to be used to test new materials and anti-inflammatory 
treatments of wear-debris induced osteolysis.[137-139] Gonҫalves, et al. used a murine 
air pouch model to investigate the inflammatory response, specifically leukocyte 
infiltration, of titanium dioxide nanoparticles at early endpoints (3-24 hours after particle 
injection). In the study, nanoparticles (anatase, 90% sized 1-10 nm diameter) were 
purchased from a vendor as an aqueous solution stabilized by polyacrylate sodium. At the 
3-, 6- and 9-hour timepoints, increased proportions of polymorphonuclear neutrophil cells 
(80 ± 2%, 91 ± 6%, 90 ± 6%, respectively) were observed in the nanoparticle-treated 
pouches versus control, before declining after the 9-hour timepoint.[140] 
 We propose a study of the wear debris generated from TiNT-etched surfaces and 
a follow-up in vivo study of TiNT wear particle injection, compared to particulate 
generated from unmodified (Control) surfaces. TiNT would be etched onto larger 
diameter rod stock, then sent for wear debris production at an experienced facility. Wear 
debris analysis would provide details regarding the particle sizing range and frequency 
and an endotoxin assay would be performed. Particles from each TiNT morphology 
(Aligned TiNT and Trabecular TiNT) and Control groups would be separately suspended, 
as described, and injected into murine air pouches implanted with calvaria bone tissue for 
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the prescribed endpoints. Pouch thickness and cell content would be measured at the 
prescribed endpoints of 2, 7, and 14 days. Additionally, TRAP, H&E, and Masson’s 
trichrome staining would be performed on the calvaria tissue to assess osteoclastic 
activity and bone loss.  
 A potential follow-up study would include injecting wear debris into the 
intramedullary canal of mice femora to simulate in vivo wear debris production. In this 
model, particles could be labelled in order to track permeation and migration.[141, 142]  
 
7.4. Proposed Concept 3:  Bone Formation and Biocompatibility Studies in Higher 
Phylogenetic Order Species 
 
 The initial in vivo studies we conducted were in rat models of intramedullary 
fixation, in order to stimulate total joint arthroplasty. In order to move toward United 
States Food and Drug Administration approval of this technology, experiments must be 
performed using a higher phylogenic order species. We propose the use of a goat model 
of total hip arthroplasty. 
 Several studies have used this model.[143-146] In a series of three experiments, 
Harboe, et al. described the use of this model. All studies used a 6-month postoperative 
endpoint. In a 2012 study, the authors tested bone-implant interface strength of an 
innovative design of an uncemented femoral stem by pull-out testing, using a technique 
analogous to the wire pull-out method described in Chapter 6. Acetabular cups/liners and 
femoral heads developed for veterinary use in canines were substituted for the other total 
hip arthroplasty components.[144] The group’s second study characterized both bony 
apposition and femoral stem pull-out testing on femoral stems coated with hydroxyapatite 
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and calcium phosphate. Following total hip arthroplasty, the gait of the goats was scored 
with a modified de Waal score.[147] At endpoint, the femoral stems were subjected to 
biomechanical pull-out testing and bone samples were harvested from the proximal collar 
of the stem. These bone samples were paraffin-embedded and imaged via light 
microscopy to assess bone structure as well as cellular activity indicative of an adverse 
reaction to the coatings.[145] Finally, bone samples were collected for histologic 
characterization. Samples were decalcified with ethylenediaminetetraacetic acid (EDTA) 
and stained with hematoxylin erythrosine saffron (HES), and then graded for bone 
apposition to the stem as well as necrosis. The presence or absence of cellular structures, 
including leukocytes and macrophages, was also evaluated.[146] 
 We propose a study replicating the characterization methods described in Chapter 
6, using total hip arthroplasty components developed for use in the canine population 
(e.g. BioMedtrix Universal Hip CFX). Preoperatively, goats will be weighed and undergo 
load-bearing measurements of the operative limb, in order to obtain baseline data.[148, 
149] Femoral stems would be etched with titania nanotubes on the implanted surface 
distal to the collar, then implanted using a defined surgical procedure.[144] Goats would 
be randomized to receive a Trabecular TiNT-etched, Aligned TiNT-etched, or Control 
implant. Each week, all postoperative goats will be weighed and assessed for load-
bearing of the operative limb. At a single, 6-month endpoint, harvested femora would be 
randomized to either the biomechanical testing cohort or imaging/histologic analysis 
cohort. Femora randomized to biomechanical would undergo femoral stem pull-out 
testing, as described by Harboe, et al.[144-146] Femora in the imaging/histologic 
analysis cohort would be immersed in 10% neutral buffered formalin for 1 week to fix all 
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tissues, then rinsed with PBS and stored in ethanol. Femora would first be scanned with 
μCT (vivaCT-80, Scanco USA, Wayne, PA). Femora would then be sectioned in three 
regions, proximal, midshaft, and distal. After embedding each section, backscattered 
electron imaging would be performed on each section to assess bone-implant contact. 
Blocks would then be polished, and thin (5 μm), transverse sections would be cut from 
the proximal, midshaft, and distal regions (n=6 sections per region). Sections would be 
stained with SBVG (n=3) or H&E (n=3). SBVG-stained sections would be used both to 
assess bone-implant contact and overlay each matched μCT slice, in order to determine 
quantitative correlations between imaging and histologic analyses. H&E-stained section 
would be used for cellular analysis to assess biocompatibility, as described in Chapter 5.   
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Chapter 8: 
Conclusions 
   
 
 The need for implant surfaces capable of both early and robust osseointegration 
will continue to rise as joint arthroplasty and other surgical procedures requiring bone 
ingrowth continue to increase annually. Over the term of implantation, wear debris is 
generated that can affect implant stability via wear debris-induced osteolysis. 
Development of materials that produce less wear debris or stimulate a decreased 
inflammatory response are desirable, in order to reduce the revision rates.  
 Titanium has historically been used as a material in orthopaedic surgery, due to its 
suitable mechanical and biocompatibility properties. Using a multifaceted approach, our 
study focused on translation between in vitro and in vivo experiments to assess the 
biocompatibility and osseointegrative potential of titania nanotube (TiNT) surfaces, 
etched from a clinically-relevant titanium alloy, were investigated.  
 In vitro testing centered on seeding rat-derived bone marrow cells (BMC; 
Sprague-Dawley strain) onto titania nanotube surfaces, in order to assess cell attachment, 
cell morphology, alkaline phosphatase (ALP) activity, osteocalcin expression as well as 
upregulation of specific genes. The BMC cells used in in vitro experiments are the same 
cell population in contact with implants in the subsequent in vivo experiments. Cell 
staining (Actin Green and DAPI) showed greater cell attachment and spreading, and 
indirectly cell viability, on TiNT surfaces at early timepoints. Cell nuclei staining (DAPI) 
indicated that smaller cell diameter and greater cell eccentricity on TiNT surfaces. Assays 
measured increased ALP activity and osteocalcin expression on TiNT surfaces at 
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multiple timepoints through 21 days, and indication that BMC differentiated toward an 
osteoblastic phenotype. Gene-level analysis showed upregulation of three genes related to 
bone formation, Col1a1, IGF-1, and osteonectin, through 21 days.    
 In vivo testing was performed in a clinically-relevant rat model of intramedullary 
fixation and focused on two themes, material-level biocompatibility and biologic 
response as well as osseointegration. An outbred rat strain, Sprague Dawley, was selected 
to approximate differences in osseointegrative potential analogous to the human 
population.  
The in vivo biocompatibility study included animal general health assessments, 
specifically related to longitudinal weight again of animals, as well as remote organ 
weight, metal ion level (i.e. remote organs, whole blood), hematologic and undecalcified 
histologic analyses. No animals were flagged for problematic weight loss or systemic 
disease during the 12-week experiment. At two weekly weight assessments, 9 and 11 
weeks postoperative, there were significant differences between animal weights, but the 
weights recovered by experiment endpoint. There were no significant differences in 
remote organ weights at endpoint. Metal ion analysis showed that Aligned TiNT and 
Trabecular TiNT had greater aluminum and vanadium content and lower titanium 
content, by wt%, compared to Control. The only significant finding from the metal ion 
analyses of remote organs and whole blood was elevated aluminum in lungs of the 
Trabecular TiNT-implanted group. Hematologic analysis, performed at endpoint, showed 
no significant differences between TiNT groups and Control. Significant differences in 
cell populations between the TiNT groups and Control were measured during 
undecalcified histologic analysis. In the TiNT-implanted femora, the periprosthetic tissue 
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demonstrated fewer inflammatory cellular activity, including fewer foreign body 
giant/multinucleated, eosinophil/basophil, and neutrophil cells, compared to Control. No 
significant differences were found in monocyte and lymphocyte activity between groups. 
 The in vivo osseointegration study used multiple characterization methods to 
assess bone ingrowth and ongrowth, including biomechanics, microcomputed 
tomography (μCT) undecalcified histology, and backscattered electron imaging (BEI) 
characterization. Wire pull-out testing demonstrated greater strength of fixation in the 
TiNT-implant femora than internal Controls, on average. The maximum failure loads and 
strength of fixation were significantly greater in the TiNT groups than internal Controls 
at the 4-week endpoint, and greater, on average, at the 12-week endpoint. μCT analysis 
indicated that total bone volume and bone volume fraction both increased more rapidly 
from the 4- to 12-week endpoints in TiNT-implanted femora, compared to internal 
Controls, in both the Distal and Midshaft volumes of interest (VOI). At the 12-week 
endpoint, Aligned TiNT implants demonstrated increased bone formation compared to 
internal Controls, with a ratio of 1.3, in the Distal VOI; however, bone formation was 
nearly equivalent between Trabecular TiNT and internal Controls. The Midshaft VOI 
demonstrated greater total bone volume and bone volume fraction ratios in both TiNT-
implanted groups compared to internal Controls. Bone-implant contact measured on 
undecalcified histologic sections showed 1.5-fold increase in TiNT-implanted femora, 
compared to internal Controls, at 12 weeks. BEI analysis was approximately analogous to 
the undecalcified histology results in the distal femora region of interest. In the midshaft, 
the results were highly variable, as indicated by line profile plots.  
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In the chapter regarding future work, three proposals were presented. One 
concept, focusing on local delivery of SDF-1β from TiNT surfaces to increase stem cell 
recruitment and subsequent bone formation, is underway. Two additional concepts are 
continuations of the experiments presented in this document. A murine air pouch model 
of wear debris-induced osteolysis would provide more information regarding the 
biocompatibility of TiNT surfaces and biologic response to TiNT wear debris. To 
generate additional data regarding osseointegration, a model of total hip arthroplasty in a 
goat is proposed. 
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